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Supplemental Methods 
 
Brief description of the participating cohorts in the Lung Cancer Cohort Consortium (LC3) 
 
We invited all prospective cohort studies that in 2009 were members in the US National Cancer Institute 
(NCI) Cohort Consortium to participate in the Lung Cancer Cohort Consortium (LC3). Additional inclusion 
criteria included the occurrence of at least 200 incident lung cancer cases with baseline questionnaire data 
and either plasma or serum samples cryopreserved at <80°C available. Twenty cohorts fulfilled those criteria 
and accepted to participate, resulting in a combined cohort population of over 2,000,000 participants from 
North America, Europe, Asia and Australia. The present work included the healthy controls, selected by 1-1 
matching with lung cancer cases, from each cohort. 
 
1) US cohorts 
The Women’s Health Initiative (WHI) 
WHI is a long-term health study of 161,808 post-menopausal women aged 50 to 79 years at 40 clinical 
centers throughout the U.S.  WHI comprises a Clinical Trial (CT) component (68,132 women), and an 
Observational Study (OS) component (93,676 women), and has included several extension studies.  Some 
detailed descriptions of WHI have been previously presented (1, 2).The CT evaluated two forms of 
postmenopausal hormone therapy, a low-fat dietary pattern intervention, and calcium and vitamin D 
supplementation in a randomized, controlled fashion, in a partial factorial design. The hormone therapy 
component findings led to major reductions in the use of hormone therapy worldwide, and are thought to 
have led to noteworthy reductions in breast cancer incidence. 
 
The Southern Community Cohort Study (SCCS) 
The Southern Community Cohort Study (SCCS) (3) is a prospective cohort of African and non-African 
Americans which during 2002-2009 enrolled approximately 86,000 residents aged 40-79 years across 12 
southern states.  Recruitment occurred mainly at community health centers, institutions providing basic 
health services primarily to the medically uninsured, so that the cohort includes many adults of lower 
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income and educational status.  Each study participant completed a detailed baseline questionnaire, and 
nearly 90% provided a biologic specimen (approximately 45% a blood sample and 45% buccal cells). 
Follow-up of the cohort is conducted by linkage to national mortality registers and to state cancer 
registries. Included in the LC3 are 480 African American lung cancer case-control pairs. 
 
Prostate, Lung, Colorectal and Ovarian  Cancer Screening Trial (PLCO) 
The PLCO study, a randomized trial aimed at evaluating the efficacy of screening in reducing cancer 
mortality, recruited approximately 155,000 men and women age 55 to 74 years from 1992 to 2001 (4). 
Screening for lung cancer among participants in the intervention arm included a chest x-ray at baseline 
followed by either three annual x-rays (for current or former smokers at enrollment) or two annual x-rays 
(for never smokers); participants in the control arm received routine health care. Screening-arm 
participants provided data on sociodemographic factors, smoking behavior, anthropometric 
characteristics, medical history, and family history of cancer, as well as blood samples annually for the first 
6 years of the study (baseline [T0] and T1 through T5). Follow-up in the trial as of July 2009 was 96.7%. 
 
The New York University Women’s Health Study (NYUWHS) 
The New York University Women’s Health Study (NYUWHS) is a prospective cohort study of women 
enrolled at a mammography screening center in New York City. From March 1985 through June 1991, 
14,274 women between the ages of 34 and 65 were enrolled in the study. Because the original focus of the 
study was endogenous hormones and breast cancer, women who had taken hormone medications in the 6 
months preceding baseline enrolment were not eligible for the study. 
At the time of enrolment, data on demographics, anthropometric measures, medical history, reproductive 
and lifestyle variables were collected through self-administered questionnaires after written informed 
consent was obtained. 
 
The American Cancer Society Cancer Prevention Study-II (CPS-II) Nutrition Cohort  
The CPS-II Nutrition Cohort is a prospective study of cancer incidence and mortality among 86,404 men 
and 97,786 women.  The CPS-II Nutrition Cohort, which is described in detail elsewhere (5), was initiated in 
1992 as a subgroup of CPS-II, a prospective study of cancer mortality involving approximately 1.2 million 
Americans begun in 1982.  Participants in the CPS-II Nutrition Cohort were recruited from CPS-II members 
who resided in 21 states and were between the ages of 50 and 74 years.  At enrollment in 1992/1993, 
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participants completed a self-administered questionnaire that included demographic, medical, dietary, and 
lifestyle information.  Follow-up questionnaires were sent to all living Nutrition Cohort members in 1997, 
and every two years after this to update exposure information and to ascertain newly diagnosed cancers.   
Between June 1998 and June 2001, blood samples were collected from a subset of CPS-II Nutrition Cohort 
participants (21,965 women and 17,411 men).   
 
 
The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease 
(CLUE II). 
The CLUE studies include two large cohorts of volunteers from Washington County, Maryland that were 
enrolled in 1974 and 1989, respectively.  CLUE I was conducted in Washington County, Maryland, in the fall 
of 1974. Brief health histories and blood pressures were taken and 15 ml of blood was drawn from 26,147 
volunteers (23,951 were residents of Washington County) at the time of enrollment. Linkage of the records 
from this program to those of a private census in the summer of 1975 indicated that almost a third of the 
adult population of the county had participated. CLUE II was an outgrowth of CLUE I conducted from May 
through October in 1989. As in CLUE I, a brief health history was obtained and 20 ml of blood was drawn. A 
blood sample was collected from 32,894 volunteers at the time of enrollment (25,076 were residents of 
Washington County). Participants were also given a food frequency questionnaire to complete at home 
and were asked to return it with a toenail clipping of the large toe for trace metal assays. Comparisons with 
published figures from the 1990 Census indicted that approximately 30 percent of adult residents had 
participated.  
 
The Multiethnic Cohort (MEC) 
The MEC includes over 215,000 men and women aged 45-75 years at recruitment from five different 
racial/ethnic groups (African Americans, Japanese Americans, Native Hawaiians, Latinos and European 
Americans) in Hawaii and California (6). The cohort was assembled in 1993-1996 by mailing a self-
administered, 26-page questionnaire to obtain extensive information on demographics, medical and 
reproductive histories, medication use, family history of various cancers, physical activity and diet.  
 
Women’s Health Study (WHS) 
The WHS was a randomized trial of low-dose aspirin, vitamin E, and beta-carotene in the primary 
prevention of cardiovascular disease and cancer beginning in 1992 among 39,876 female US health 
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professionals aged ≥45 years (7). Information on major clinical, lifestyle, and dietary factors was collected 
via self-reports on baseline questionnaires. Women also provided baseline bloods.  
 
Physicians’ Health Study (PHS) 
The PHS I began in 1982 as a randomized trial of aspirin and beta-carotene for the primary prevention of 
heart disease and cancer among 22,071 male, Caucasian physicians initially aged 40 to 84 years (8), 
followed by the PHS II trial beginning in 1997 to evaluate beta-carotene, vitamin C, vitamin E, and a daily 
multivitamin on the prevention of cancer, CVD, and other endpoints. The PHS II included 14,641 men, with 
7,641 participants from the PHS I plus 7,000 new physicians, for a total of 29,071 PHS participants (9). A 
wide range of demographic, clinical, and lifestyle factors were assessed via baseline questionnaires, along 
with baseline bloods.  
 
The Nurses’ Health Study (NHS) 
The Nurses’ Health Study (NHS) (10, 11) was established in 1976, when 121,700 married female registered 
nurses aged 30 to 55 years residing in 11 States in the U.S. completed and returned a self-administered 
questionnaire. Questionnaires have been mailed to participants in both cohorts every 2 years since 
baseline to collect updated information on demographics, lifestyle factors, medical history, and disease 
outcomes. A semi quantitative food frequency questionnaire (FFQ) was administered to obtain information 
on usual dietary intake over the previous year. The reproducibility and validity of the FFQs have been 
established (12-16). The FFQ was first administered in 1980 in the NHS, and were repeated almost every 4 
years thereafter. For each food item, the questionnaire specified a common serving size and queried 
respondents on average intake during the previous year; responses in 9 categories ranged from almost 
never to 6 or more per day. Most nutritional variables measured by these FFQs have been developed, 
tested, and refined by our group over the past 30 years (https://regepi.bwh.harvard.edu/health/).  
The follow-up rate has been greater than 90%. The institutional review board at the Brigham and Women’s 
Hospital approved the study. As approved by the committee, return of the questionnaires was considered 
to imply informed consent.  
 
Health Professionnals Follow-up Study (HPFS) 
The Health Professionals Follow-up Study (HPFS) (17) is an ongoing cohort study of 51,529 U.S. male 
professionals who were aged 40 to 75 years at baseline in 1986. Questionnaires have been mailed to 
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participants in both cohorts every 2 years since baseline to collect updated information on demographics, 
lifestyle factors, mwedical history, and disease outcomes. The follow-up rate has been greater than 90%. 
The institutional review board at the Harvard T.H. Chan School Public Health approved this study. As 
approved by the committee, return of the questionnaires was considered to imply informed consent.  A 
semiquantitative food frequency questionnaire (FFQ) was administered to obtain information on usual 
dietary intake over the previous year. The FFQ was first administered in 1986 in the HPFS and was 
repeated almost every 4 years thereafter. The reproducibility and validity of the FFQ have been estabished 
(14, 18). For each food item, the questionnaire specified a common serving size and queried respondents 
on average intake during the previous year; responses in 9 categories ranged from almost never to 6 or 
more per day.  
 
2) Nordic cohorts 
The Malmö Diet and Cancer Study (MDCS) 
The Malmö Diet and Cancer Study (MDCS) is a population-based prospective cohort study that between 
1991 and 1996 recruited men and women aged 44 to 74 years of age living in Malmö, Sweden (19). The 
main goal of the MDCS is to study the impact of diet on cancer incidence and mortality. In total 28098 
individuals completed all baseline examinations, which consisted of dietary assessment using a modified 
diet history method including a 7-day food record on lunch and dinner meals, a self-administered 
questionnaire covering lifestyle and socioeconomic factors, anthropometric measurements and collection 
of blood samples.  
 
The Northern Sweden Health and Disease Study Cohort (NSHDS) 
The Northern Sweden Health and Disease Study (NSHDS) encompasses several prospective cohorts, the 
current study involving study participants from the Västerbotten Intervention Project (VIP), a sub-cohort 
within NSHDS (20). VIP is an ongoing prospective cohort and intervention study intended for health 
promotion of the general population of the Västerbotten County in northern Sweden. VIP was initiated in 
1985 and all residents in the Västerbotten County were invited to participate by attending a health check-
up at 40, 50 and 60 years of age. Participants were asked to complete a self-administered questionnaire 
including various demographic factors such as education, smoking habits, physical activity and diet. In 
addition, height and weight were measured and participants were asked to donate a fasting blood sample 
for future research. 
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The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) 
The ATBC Study was a randomized, double-blind, placebo-controlled, primary cancer prevention trial 
testing daily supplementation with α-tocopherol (50 mg/day) or β-carotene (20 mg/day), or both (21). 
Between 1985 and 1988, the study enrolled and randomized 29,133 50-69 year old male cigarette smokers 
from southwestern Finland.  Study supplementation continued for 5-8 years (median 6.1 years) until death 
or trial closure (April 30, 1993).   At baseline, participants completed questionnaires regarding general risk 
factors, medical history, smoking habits, and dietary intake.  Height, weight, heart rate, and blood pressure 
were measured by trained nurses and fasting serum samples were collected and stored at –70 oC. 
 
The Nord-Trøndelag Health Study (HUNT) 
The HUNT study is a longitudinal population based study having invited all persons aged 20-100 years living 
in the county of Nord-Trøndelag, Norway to three data collections, HUNT1 (1984-86), HUNT2 (1995-97) 
and HUNT 3 (2006-08) (http://www.ntnu.edu/hunt).  Comprehensive data on life style, health status, 
symptoms, diseases and anthropometrics have been collected through questionnaires, interviews and 
clinical examinations, and in HUNT2 and HUNT3 biological material as blood and urine additionally were 
collected and stored. 
 
 
3. Asian cohorts 
The Shanghai Men’s Health Study (SMHS) and the Shanghai Women’s Health Study (SWHS) 
The SMHS and SWHS are population-based cohort studies conducted in eight communities of urban 
Shanghai. Their designs and methods have been described elsewhere (22, 23). 
Briefly, the SWHS recruited 74,941 women during 1997-2000 (response rate: 93%) and the SMHS recruited 
61,480 men during 2002-2006 (response rate: 74%). Similar methods and questionnaires were used in both 
studies. At baseline in-person interviews, information on sociodemographic, diet, lifestyle, occupation and 
medical history was obtained; height, body weight, and waist circumference were measured. Blood 
samples were collected from 75% of the study participants in both studies, processed within 6 hours, and 
stored at -70℃ until analysis.  
Online Supplemental Material 
 
 
The SMHS and SWHS have been followed up by annual record linkage with the population-based Shanghai 
Cancer Registry and Shanghai Vital Statistics Registry and in-person surveys every 2-3 years. Exposure 
information, including dietary intake, was updated in the in-person follow-up surveys.  All possible matches 
from the linkages are checked manually and verified by home visits. Medical charts were obtained from 
the initial diagnostic hospitals to verify cancer diagnosis.  Death certificate data from the Shanghai Vital 
Statistics Unit was used to identify the primary cause of death. 
The studies were approved by the Institutional Review boards of the Shanghai Cancer Institute and 
Vanderbilt University. Informed consent was obtained from all participants.        
 
The Singapore Chinese Health Study (SCHS) 
The design of the SCHS study has been described (24, 25). Briefly, the cohort was drawn from permanent 
residents or citizens of Singapore who resided in government-built housing estates (86% of the Singapore 
population reside in such facilities). The eligible age range for cohort enrolment was 45-74 years. We 
restricted study subjects to the two major dialect groups of Chinese in Singapore: the Hokkiens and the 
Cantonese, who originated from Fujian and Guangdong provinces in Southern China, respectively. Between 
April 1993 and December 1998, 63,257 subjects (approximately 85% of eligible subjects) were enrolled into 
the cohort study.  At recruitment, each study subject was interviewed in person by a trained interviewer 
using a structured questionnaire that emphasized current diet assessed via a validated, 165-item food 
frequency questionnaire. The questionnaire also requested information on demographics, lifetime use of 
tobacco, incense use, current physical activity, usual sleep duration, reproductive history (women only), 
occupational exposure, medical history, and family history of cancer.   
Beginning in April 1994, a random 3% sample of cohort participants were asked to provide blood or buccal 
cell (if request for blood sample was denied), and spot urine samples. Eligibility for this biospecimen 
subcohort was extended to all surviving cohort participants starting in January 2000. By April 2005, all 
surviving cohort subjects had been contacted for biospecimen donation. Approximately 60% of eligible 
cohort participants donated biospecimens.  
The cohort has been passively followed for death and cancer occurrence through regular record linkage 
with the population-based Singapore Cancer Registry and the Singapore Registry of Births and Deaths. 
Migration out of Singapore, especially among housing estate residents, is negligible.  As of latest update, 
only 55 individuals from this cohort were known to be lost to follow-up due to migration and other reason.   
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The Shanghai Cohort Study (SCS) 
The SCS study is a residential cohort of 18,244 men in Shanghai, China, assembled during 1986-89 when 
subjects were between the ages of 45 and 64 years. Approximately 80% of eligible men participated in the 
study. At the time of recruitment, each cohort subject was interviewed in-person by a trained nurse 
interviewer using a structured questionnaire that included background information, history of tobacco and 
alcohol use, current diet, and medical history (26, 27). 
At the completion of the interview, the nurse collected a 10 ml blood and a single void urine specimen 
from the study participant.  Blood and urine samples were kept in insulated boxes with ice (0-2oC).  The 
serum was separated from blood specimen within 3-4 hours after collection. Two sets of serum (2 ml and 1 
ml, respectively) and two sets of urine samples (10 ml each) per subject have been stored at -80oC. 
The cohort has been followed for the occurrence of cancer and death through routine ascertainment of 
new cases from the population-based Shanghai Cancer Registry and Shanghai Vital Statistics Units. To 
maximize the cancer findings and minimize the loss of follow-up, we have recontacted each surviving 
cohort member annually. Retired nurses visit the last known address of each living cohort member and 
record details of the interim health history of the cohort member. As of December 31, 2014, cumulatively 
612 (3.4%) original subjects were lost to follow-up (i.e., persons we have no record of death and we have 
been unable to locate through our annual follow-up recontacts), and 574 (3.1%) refused to our continued 
follow-up interview (their cancer and vital status has been continually updated through record linkage 
analyses) after 26 years of follow-up since the beginning of the study. 
4. Australian cohort 
The Melbourne Collaborative Cohort Study (MCCS) 
The MCCS is a prospective cohort study of 41,514 participants (17,045 men and 24,469 women) aged 27-
88 years at recruitment (28); 99.3% of whom were aged 40-69 years.  Recruitment occurred between 1990 
and 1994.  Southern European migrants to Australia (including 5,411 Italians and 4,525 Greeks) were over-
sampled to extend the range of lifestyle exposures and to increase genetic variation. 
Subjects were recruited via Electoral Rolls (registration to vote is compulsory for adults in Australia), 
advertisements, and community announcements in local media.  Comprehensive lists of Italian and Greek 
surnames were used to target southern European migrants in phonebooks and electoral rolls.  Passive 
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follow-up of the cohort has been conducted by record linkage to Electoral Rolls, electronic phonebooks, 
the Victorian Cancer Registry and death records; as well as national cancer and death records to identify 
events outside of Victoria. 
At recruitment participant’s height and weight were measured, blood samples collected and 
questionnaires covering lifestyle (diet, smoking, physical activity and alcohol consumption), demographics 
and medical history completed. 
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SUPPLEMENTAL TABLE 1 
Baseline characteristics of study participants by cohort 
Region  US 
Cohort1  WHI SCCS PLCO NYUWHS CPS-II CLUE MEC WHS NHS HPFS PHS 
Number, n 241 226 450 171 182 191 174 181 345 155 81 
Sex (female), n (%) 241 (100.0) 79 (35.0) 140 (31.1) 171 (100.0) 99 (54.4) 85 (44.5) 65 (37.4) 181 (100.0) 345 (100.0) 0 (0.0) 0 (0.0) 
Age (years, mean (5th-95th percentile)) 
68.0 
(55.0, 79.0) 
53.8 
(44.0, 71.0) 
67.0 
(59.0, 75.0) 
56.0 
(41.0, 64.0) 
70.0 
(62.0, 79.0) 
60.0 
(43.0, 75.0) 
73.5 
(59.0, 83.0) 
57.0 
(47.0, 70.0) 
61.0 
(48.2, 68.0) 
67.0 
(50.7, 76.3) 
70.0 
(56.0, 81.0) 
Education, n (%)            
 Less than high school 15 (6.2) 99 (43.8) 4 (0.9) 6 (3.7) 8 (4.4) 66 (34.6) 17 (9.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Completed high school 57 (23.7) 66 (29.2) 31 (6.9) 60 (36.8) 37 (20.4) 84 (44.0) 39 (22.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Vocational school 19 (7.9) 10 (4.4) 110 (24.4) 3 (1.8) 16 (8.8) 0 (0.0) 11 (6.3) 23 (12.9) 243 (73.4) 0 (0.0) 0 (0.0) 
 Some college 56 (23.2) 38 (16.8) 56 (12.4) 41 (25.2) 53 (29.3) 21 (11.0) 31 (17.8) 94 (52.8) 0 (0.0) 0 (0.0) 0 (0.0) 
 College graduate 21 (8.7) 9 (4.0) 100 (22.2) 14 (8.6) 28 (15.5) 12 (6.3) 38 (21.8) 32 (18.0) 65 (19.6) 0 (0.0) 0 (0.0) 
 Graduate studies 73 (30.3) 4 (1.8) 75 (16.7) 39 (23.9) 39 (21.5) 8 (4.2) 38 (21.8) 29 (16.3) 23 (6.9) 155 (100.0) 81 (100.0) 
 Unknown 0 (0.0) 0 (0.0) 73 (16.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Smoking status, n (%)            
 Never 241 (100.0) 17 (7.5) 50 (11.1) 30 (17.5) 41 (22.5) 33 (17.3) 38 (21.8) 33 (18.2) 43 (12.5) 18 (11.6) 25 (30.9) 
 Former 0 (0.0) 44 (19.5) 290 (64.4) 70 (40.9) 106 (58.2) 70 (36.6) 90 (51.7) 67 (37.0) 126 (36.5) 95 (61.3) 48 (59.3) 
 Current 0 (0.0) 165 (73.0) 110 (24.4) 71 (41.5) 35 (19.2) 88 (46.1) 46 (26.4) 81 (44.8) 176 (51.0) 42 (27.1) 8 (9.9) 
BMI2 (kg/m2, median (5th-95th percentile)) 25.7 
(19.9, 38.0) 
26.9 
(20.0, 41.4) 
26.7 
(21.1, 35.7) 
23.6 
(19.5, 31.6) 
26.6 
(20.8, 33.2) 
25.4 
(20.1, 33.0) 
25.2 
(20.2, 33.2) 
24.3 
(19.8, 31.8) 
24.2 
(19.7, 33.8) 
26.6 
(21.7, 33.4) 
25.1 
(21.7, 31.9) 
MV use, all participants, n (%)            
 Never 0 (0.0) 0 (0.0) 325 (72.2) 84 (49.1) 0 (0.0) 0 (0.0) 77 (44.3) 0 (0.0) 0 (0.0) 0 (0.0) 41 (50.6) 
 Ever 0 (0.0) 0 (0.0) 57 (12.7) 86 (50.3) 0 (0.0) 0 (0.0) 97 (55.7) 0 (0.0) 0 (0.0) 0 (0.0) 29 (35.8) 
 No current 131 (54.4) 161 (71.2) 0 (0.0) 0 (0.0) 76 (41.8) 160 (83.8) 0 (0.0) 114 (63.0) 196 (56.8) 76 (49.0) 0 (0.0) 
 Current 110 (45.6) 64 (28.3) 0 (0.0) 0 (0.0) 95 (52.2) 31 (16.2) 0 (0.0) 60 (33.1) 133 (38.6) 78 (50.3) 0 (0.0) 
 Missing 0 (0.0) 1 (0.4) 68 (15.1) 1 (0.6) 11 (6.0) 0 (0.0) 0 (0.0) 7 (3.9) 16 (4.6) 1 (0.6) 11 (13.6) 
MV use in those with available data, n (%)            
 No (Never+No current) 131 (54.4) 161 (71.6) 325 (85.1) 84 (49.4) 76 (44.4) 160 (83.8) 77 (44.3) 114 (65.5) 196 (59.6) 76 (49.4) 41 (58.6) 
 Yes (Ever+Current) 110 (45.6) 64 (28.4) 57 (14.9) 86 (50.6) 95 (55.6) 31 (16.2) 97 (55.7) 60 (34.5) 133 (40.4) 78 (50.6) 29 (41.4) 
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SUPPLEMENTAL TABLE 1 (CONTINUED)        
Region  Nordic  Asia   Australia  
Cohort1  MDCS NSHDS ATBC HUNT  SCS3 SCHS SMHS SWHS   MCCS4 P 
Numbers, n 198 244 200 193  513 379 421 416   353  
Sex (female), n(%) 109 (55.1) 121 (49.6) 0 (0.0) 130 (67.4)  0 (0.0) 99 (26.1) 0 (0.0) 416 (100.0)   141 (39.9) <0.001 
Age (years, mean (5th-95th percentile)) 
61.7 (49.1, 
71.3) 
59.8 (40.2, 
60.3) 
60.0 (51.0, 
67.0) 
59.1 (38.8, 
76.6) 
 
58.0 (47.6, 
64.0) 
68.0 (57.0, 
78.0) 
66.0 (45.0, 
73.0) 
62.0 (43.0, 
69.0) 
  61.0 (45.0, 
67.4) 
<0.001 
Education, n (%)              
 Less than high school 91 (46.4) 110 (45.6) 63 (31.5) 101 (53.7)  366 (71.3) 370 (97.6) 15 (3.6) 92 (22.1)   232 (65.7) <0.001 
 Completed high school 49 (25.0) 33 (13.7) 1 (0.5) 60 (31.9)  78 (15.2) 6 (1.6) 49 (11.9) 94 (22.6)   37 (10.5)  
 Vocational school 14 (7.1) 72 (29.9) 81 (40.5) 0 (0.0)  17 (3.3) 3 (0.8) 154 (37.4) 103 (24.8)   33 (9.3)  
 Some college 42 (21.4) 26 (10.8) 43 (21.5) 9 (4.8)  0 (0.0) 0 (0.0) 111 (26.9) 85 (20.4)   9 (2.5)  
 College graduate 0 (0.0) 0 (0.0) 12 (6.0) 10 (5.3)  52 (10.1) 0 (0.0) 38 (9.2) 23 (5.5)   42 (11.9)  
 Graduate studies 0 (0.0) 0 (0.0) 0 (0.0) 8 (4.3)  0 (0.0) 0 (0.0) 45 (10.9) 19 (4.6)   0 (0.0)  
 Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0)  
Smoking status, n (%)              
 Never 50 (25.3) 30 (12.3) 0 (0.0) 27 (14.0)  51 (9.9) 80 (21.1) 49 (11.6) 381 (91.6)   49 (13.9) <0.001 
 Former 71 (35.9) 76 (31.1) 0 (0.0) 43 (22.3)  11 (2.1) 89 (23.5) 71 (16.9) 5 (1.2)   145 (41.1)  
 Current 77 (38.9) 138 (56.6) 200 (100.0) 123 (63.7)  451 (87.9) 210 (55.4) 301 (71.5) 30 (7.2)   159 (45.0)  
BMI2 (kg/m2, median (5th-95th percentile)) 
24.8 
(20.1, 30.8) 
26.0 
(20.5, 33.9) 
26.2 
(20.9, 32.1) 
26.3 
(20.3, 34.5) 
 
21.6 
(17.9, 27.6) 
22.8 
(18.2, 27.1) 
23.7 
(18.7, 29.0) 
24.4 
(19.5, 30.2) 
  27.5 
(21.2, 35.6) 
<0.001 
MV use, all participants, n (%)              
 Never 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0) <0.001 
 Ever 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0)  
 No current 0 (0.0) 113 (46.3) 0 (0.0) 37 (19.2)  0 (0.0) 0 (0.0) 386 (91.7) 393 (94.5)   306 (86.7)  
 Current 0 (0.0) 27 (11.1) 0 (0.0) 28 (14.5)  0 (0.0) 0 (0.0) 35 (8.3) 23 (5.5)   47 (13.3)  
 Missing 198 (100.0) 104 (42.6) 200 (100.0) 128 (66.3)  513 (100.0) 379 (100.0) 0 (0.0) 0 (0.0)   0 (0.0)  
MV use in those with available data, n (%)              
 No (Never+No current) n.a. 113 (80.7) n.a. 37 (56.9)  n.a. n.a. 386 (91.7) 393 (94.5)   306 (86.7)  
 Yes (Ever+Current) n.a. 27 (19.3) n.a. 28 (43.1)  n.a. n.a. 35 (8.3) 23 (5.5)   47 (13.3)  
1ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CLUE, The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American Cancer 
Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health Professionals Follow-up Study; HUNT, The Nord-Trøndelag Health Study; MCCS, The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer 
Study; MEC, The Multiethnic Cohort; NHS, The Nurses’ Health Study; NSHDS, The Northern Sweden Health and Disease Study Cohort; NYUWHS, The New York University Women’s Health Study; PHS, Physicians’ Health Study; 
PLCO, Prostate, Lung, Colorectal and Ovarian  Cancer Screening Trial; SCCS, The Southern Community Cohort Study; SCHS, The Singapore Chinese Health Study; SCS, The Shanghai Cohort Study; SMHS, The Shanghai Men’s 
Health Study; SWHS, The Shanghai Women’s Health Study; WHI, The Women’s Health Initiative; WHS, Women’s Health Study. 
2BMI was calculated as weight/height2.  
3SCS consisted of ethnic Chinese only. 
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4MCCS consisted of 75% Australian born, and 25% direct immigrants from Italy and Greece.  
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SUPPLEMENTAL TABLE 2 
Crude geometric mean (5,95 percentiles) biomarker concentrations for the total population and by geographic region1 
Region Total 
 
US Nordic Asia Australia 
Number, n 5314 
 
2397 835 1729 353 
Vitamin scores 
      
 
TVS 
  
0.45 
(-1.24, 2.19) 
-0.12 
(-1.17, 1.14) 
-0.56 
(-1.76, 0.78) 
-0.01 
(-1.03, 0.99) 
 
BVS 
  
0.43 
(-1.18, 2.30) 
-0.41 
(-1.57, 0.95) 
-0.34 
(-1.54, 1.01) 
-0.27 
(-1.35, 0.94) 
 
FVS 
  
0.33 
(-1.36, 1.79) 
0.26 
(-0.87, 1.37) 
-0.64 
(-2.03, 0.81) 
0.30 
(-0.81, 1.39) 
Vitamins 
      
 
B2 (nmol/L) 20.3 
(5.8, 89.6)  
23.9 
(7.2, 116.7) 
16.1 
(5.3, 47.5) 
17.8 
(4.7, 74.1) 
22.2 
(9.3, 62.8) 
 
PLP (nmol/L) 41.3 
(13.8, 195.5)  
54.7 
(16.4, 270.9) 
32.5 
(13.1, 101.1) 
32.4 
(12.2, 117.8) 
34.4 
(14.3, 110.4) 
 
PL (nmol/L) 17.4 
(5.2, 112.7)  
22.3 
(4.5, 184.5) 
15.1 
(6.0, 52.3) 
13.1 
(5.3, 47.3) 
17.8 
(9.2, 56.0) 
 
PA (nmol/L) 25.2 
(6.7, 187.4)  
41.2 
(10.2, 323.8) 
22.6 
(10.9, 80.8) 
13.7 
(4.5, 62.6) 
22.3 
(11.0, 72.0) 
 
Folate (nmol/L) 20.0 
(6.3, 90.3)  
32.1 
(8.1, 114.8) 
10.6 
(4.8, 28.7) 
15.3 
(6.7, 40.5) 
13.7 
(5.5, 35.2) 
 
B12 (pmol/L) 428 
(232, 768)  
442 
(230, 810) 
465 
(263, 790) 
398 
(227, 681) 
401 
(242, 659) 
 
Vit A (µmol/L) 2.11 
(1.32, 3.15)  
2.23 
(1.44, 3.30) 
2.32 
(1.61, 3.23) 
1.84 
(1.17, 2.82) 
2.29 
(1.60, 3.24) 
 
Vit D (nmol/L) 54.5 
(25.5, 101.5)  
60.3 
(25.9, 110.7) 
58.1 
(30.2, 100.9) 
45.5 
(23.1, 84.1) 
56.8 
(31.5, 97.4) 
 
aTOC (µmol/L) 30.6 
(17.4, 58.4)  
34.5 
(19.4, 67.0) 
31.9 
(21.1, 50.2) 
24.7 
(15.8, 41.3) 
34.4 
(23.3, 55.2) 
 
gTOC (µmol/L) 3.66 
(1.04, 9.95)  
4.12 
(0.94, 10.80) 
3.02 
(1.22, 7.30) 
3.81 
(1.11, 9.87) 
2.10 
(0.90, 5.05) 
One-carbon metabolites  
      
 
tMet (µmol/L) 26.8 
(18.6, 40.4)  
26.6 
(18.8, 39.7) 
26.1 
(18.5, 38.1) 
27.4 
(18.0, 42.1) 
26.8 
(19.6, 36.8) 
 
tHcy (µmol/L) 11.8 
(6.8, 21.9)  
11.0 
(6.4, 19.8) 
11.6 
(6.9, 20.9) 
12.8 
(7.4, 26.4) 
13.1 
(8.0, 22.0) 
 
Cysta (µmol/L) 0.205 
(0.097, 0.472)  
0.178 
(0.087, 0.400) 
0.188 
(0.097, 0.441) 
0.262 
(0.132, 0.567) 
0.195 
(0.111, 0.414) 
 
tCys (µmol/L) 296 
(232, 377)  
305 
(238, 386) 
297 
(230, 392) 
281 
(226, 348) 
304 
(253, 368) 
 
Serine (µmol/L) 120.4 
(76.6, 197.1)  
108.0 
(70.5, 163.5) 
130.8 
(84.2, 202.1) 
135.3 
(88.3, 217.7) 
117.6 
(86.8, 158.1) 
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Glycine (µmol/L) 268 
(170, 441)  
265 
(168, 440) 
266 
(165, 439) 
275 
(174, 448) 
250 
(178, 381) 
 
Choline (µmol/L) 12.9 
(8.1, 22.5)  
12.6 
(7.8, 19.5) 
12.3 
(7.4, 21.7) 
14.3 
(8.7, 28.4) 
14.7 
(9.6, 21.9) 
 
Betaine (µmol/L) 39.9 
(20.6, 69.9)  
35.9 
(17.7, 62.4) 
33.3 
(20.4, 53.8) 
51.2 
(33.1, 78.4) 
37.4 
(22.1, 59.3) 
 
DMG (µmol/L) 4.11 
(2.15, 7.88)  
3.47 
(1.87, 6.64) 
4.17 
(2.45, 7.40) 
5.17 
(3.19, 9.19) 
4.02 
(2.41, 7.10) 
Tryptophan + metabolites  
      
 
Trp (µmol/L) 65.9 
(46.2, 90.7)  
63.7 
(43.7, 90.5) 
67.8 
(49.2, 92.3) 
67.5 
(49.3, 90.4) 
68.3 
(52.3, 89.7) 
 
Kyn (µmol/L) 1.52 
(1.05, 2.22)  
1.53 
(1.02, 2.34) 
1.52 
(1.06, 2.18) 
1.50 
(1.09, 2.14) 
1.53 
(1.13, 2.17) 
 
KA (nmol/L) 44.4 
(22.0, 91.0)  
44.1 
(21.2, 92.5) 
38.5 
(20.7, 69.9) 
47.6 
(23.7, 97.6) 
46.2 
(26.1, 81.5) 
 
AA (nmol/L) 14.4 
(8.0, 29.1)  
14.7 
(8.1, 28.9) 
14.5 
(8.4, 29.1) 
13.9 
(7.6, 28.8) 
15.2 
(8.4, 30.6) 
 
HK (nmol/L) 37.1 
(20.3, 70.5)  
35.0 
(18.9, 65.2) 
37.6 
(21.6, 63.9) 
40.1 
(21.9, 81.1) 
36.7 
(22.3, 65.8) 
 
XA (nmol/L) 12.1 
(4.6, 29.1)  
11.5 
(4.2, 29.4) 
11.8 
(5.1, 26.5) 
13.0 
(5.4, 29.9) 
12.2 
(4.9, 26.5) 
 
HAA (nmol/L) 31.9 
(16.1, 59.6)  
30.2 
(14.3, 61.5) 
33.5 
(18.9, 58.7) 
33.8 
(18.1, 59.8) 
31.3 
(17.4, 53.2) 
 
QA (nmol/L) 362 
(208, 685)  
378 
(207, 741) 
336 
(197, 605) 
356 
(216, 605) 
356 
(222, 598) 
Other  
      
 
CRP (µg/L) 1.76 
(0.24, 13.17)  
2.25 
(0.30 ,14.75) 
1.57 
(0.22 ,11.09) 
1.28 
(0.20, 10.52) 
2.14 
(0.37, 11.78) 
 
KTR (nmol/µmol) 23.1 
(16.4, 34.5)  
24.0 
(16.6, 37.0) 
22.4 
(16.5, 32.2) 
22.2 
(16.0, 32.1) 
22.4 
(16.0, 31.6) 
 
PAr (PA/(PLP+PL)) 0.48 
(0.16, 1.02)  
0.58 
(0.22, 1.20) 
0.50 
(0.23, 0.94) 
0.33 
(0.11, 0.69) 
0.47 
(0.22, 0.82) 
 
Creat (µmol/L) 74.7 
(52.3, 105.3)  
74.8 
(51.3, 109.0) 
73.6 
(54.9, 97.5) 
75.4 
(52.3, 105.0) 
73.2 
(52.6, 103.0) 
 
HK/XA 3.66 
(1.39, 7.72)  
3.69 
(1.27, 8.25) 
3.66 
(1.58, 7.08) 
3.69 
(1.52, 7.16) 
3.36 
(1.46, 6.69) 
 
Cotinine (nmol/L) 44 
(0, 1868)  
18 
(0, 1963) 
153 
(0, 1693) 
81 
(1, 1780) 
47 
(0, 2070) 
 
Arginine (µmol/L) 71.8 
(28.2, 145.0)  
59.3 
(19.5, 125.0) 
96.5 
(51.2, 172.0) 
82.3 
(44.1, 144.6) 
66.5 
(37.9, 107.4) 
 
ADMA (µmol/L) 0.545 
(0.411, 0.714)  
0.529 
(0.397, 0.701) 
0.549 
(0.424, 0.703) 
0.564 
(0.435, 0.739) 
0.546 
(0.430, 0.684) 
 
SDMA (µmol/L) 0.590 
(0.408, 0.865)  
0.574 
(0.392, 0.833) 
0.566 
(0.411, 0.785) 
0.628 
(0.434, 0.933) 
0.588 
(0.448, 0.786) 
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hArg (µmol/L) 1.95 
(0.98, 3.70)  
1.76 
(0.91, 3.39) 
1.78 
(0.95, 3.26) 
2.33 
(1.30, 4.06) 
2.01 
(1.11, 3.50) 
 
MMA (µmol/L) 0.181 
(0.105, 0.385)  
0.177 
(0.109, 0.330) 
0.164 
(0.100, 0.306) 
0.199 
(0.106, 0.500) 
0.173 
(0.108, 0.317) 
1AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; BVS, B-
Vitamin Score; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; FVS, Fat-soluble Vitamin Score; TOC, -
tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, 
kynurenine/tryptophan ratio; Kyn, kynurenine; MMA, methylmalonic acid; PA, 4-pyridoxic acid; PAr, PLP/(PL+PA); PL, pyridoxal; 
PLP, pyridoxal 5'-phosphate; QA, quinolinic acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; 
tMet, total methionine; Trp, tryptophan; TVS, Total Vitamin Score; Vit A, all-trans retinol; Vit D, 25-OH vitamin D2 + season 
adjusted 25-OH vitamin D3; XA, xanthurenic acid. 
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SUPPLEMENTAL TABLE 3 
Crude geometric mean (5,95 percentiles) biomarker concentrations for US cohorts1,2 
Cohort WHI SCCS PLCO NYUWHS CPS-II CLUE MEC WHS NHS HPFS PHS 
Number, n 241 226 450 171 182 191 174 181 345 155 81 
Vitamin scores 
           
 
TVS 0.42 
(-1.09, 1.63) 
-0.56 
(-1.79, 1.06) 
0.59 
(-1.21, 2.17) 
0.71 
(-0.90, 2.75) 
1.36 
(-0.42, 3.06) 
0.17 
(-1.11, 1.63) 
1.13 
(-0.25, 2.29) 
0.11 
(-1.28, 1.59) 
0.38 
(-1.06, 1.94) 
0.37 
(-1.01, 1.82) 
0.35 
(-0.88, 1.53) 
 
BVS 0.52 
(-0.88, 2.01) 
-0.13 
(-1.33, 1.33) 
0.63 
(-1.06, 2.42) 
0.73 
(-0.97, 3.07) 
1.10 
(-0.64, 3.00) 
0.19 
(-1.20, 1.94) 
1.05 
(-0.42, 2.55) 
-0.07 
(-1.42, 1.44) 
0.26 
(-1.32, 2.10) 
0.14 
(-1.39, 2.02) 
0.14 
(-1.10, 1.43) 
 
FVS 0.16 
(-1.36, 1.43) 
-0.89 
(-2.47, 0.61) 
0.34 
(-1.30, 1.84) 
0.46 
(-0.81, 1.78) 
1.23 
(-0.34, 2.51) 
0.10 
(-1.08, 1.27) 
0.86 
(-0.28, 1.80) 
0.30 
(-1.01, 1.51) 
0.40 
(-0.95, 1.57) 
0.53 
(-0.64, 1.57) 
0.50 
(-0.70, 1.53) 
Vitamins 
           
 
B2 (nmol/L) 23.4 
(9.8, 74.6) 
15.3 
(4.6, 85.8) 
29.5 
(9.4, 131.3) 
33.3 
(9.4, 242.6) 
34.4 
(8.1, 184.3) 
25.6 
(11.8, 74.2) 
25.1 
(10.5, 68.2) 
13.3 
(4.8, 57.9) 
27.2 
(10.7, 138.1) 
18.8 
(6.1, 116.5) 
16.6 
(6.4, 76.0) 
 
PLP (nmol/L) 58.7 
(15.3, 252.3) 
40.4 
(16.7, 116.2) 
48.3 
(14.2, 250.8) 
63.3 
(14.9, 397.5) 
101.4 
(29.1, 516.4) 
44.2 
(14.7, 186.7) 
80.0 
(21.8, 312.2) 
52.5 
(19.0, 185.7) 
43.5 
(15.2, 189.3) 
65.4 
(21.7, 313.3) 
58.4 
(24.8, 136.3) 
 
PL (nmol/L) 26.6 
(8.0, 150.7) 
5.6 
(2.2, 22.3) 
35.1 
(10.6, 316.4) 
38.6 
(8.1, 1429.8) 
26.5 
(5.8, 366.9) 
27.8 
(10.5, 122.1) 
42.0 
(12.7, 184.6) 
10.2 
(4.3, 30.4) 
24.4 
(8.2, 189.4) 
14.6 
(4.3, 136.7) 
13.2 
(5.7, 55.2) 
 
PA (nmol/L) 40.3 
(11.6, 189.2) 
16.1 
(5.7, 98.2) 
50.1 
(13.6, 432.0) 
51.7 
(10.7, 1182.0) 
93.4 
(17.8, 975.9) 
32.2 
(10.2, 222.4) 
58.2 
(16.3, 269.1) 
30.3 
(12.4, 112.2) 
37.5 
(13.0, 278.1) 
45.8 
(18.2, 336.2) 
39.9 
(18.2, 161.5) 
 
Folate (nmol/L) 49.4 
(19.1, 114.1) 
19.0 
(7.8, 52.6) 
51.5 
(15.3, 137.0) 
27.9 
(7.8, 124.5) 
35.5 
(13.0, 100.0) 21.8(6.4, 89.8) 
66.6 
(26.9, 138.8) 
18.7 
(6.2, 55.2) 
26.4 
(7.3, 99.4) 
21.4 
(7.1, 61.3) 
26.3 
(8.4, 60.3) 
 
B12 (pmol/L) 389 
(172, 822) 
440 
(257, 710) 
423 
(205, 805) 
525 
(304, 944) 
551 
(296, 1764) 437(232, 743) 
502 
(246, 1094) 
445 
(254, 741) 
422 
(233, 735) 
400 
(229, 678) 
406 
(219, 697) 
 
Vit A (µmol/L) 2.02 
(1.54, 2.69) 
1.93 
(1.12, 3.30) 
2.09 
(1.27, 3.33) 
2.30 
(1.65, 3.28) 
2.69 
(1.96, 3.88) 
2.18 
(1.49, 3.13) 
2.35 
(1.79, 3.15) 
2.29 
(1.54, 3.26) 
2.31 
(1.65, 3.27) 
2.37 
(1.68, 3.10) 
2.51 
(1.80, 3.33) 
 
Vit D (nmol/L) 55.5 
(25.7, 100.9) 
35.1 
(17.1, 71.1) 
60.9 
(29.7, 110.9) 
61.2 
(30.1, 102.9) 
78.9 
(39.9, 135.6) 
61.0 
(30.7, 94.4) 
76.5 
(49.9, 112.7) 
61.6 
(29.7, 106.2) 
63.5 
(30.5, 112.2) 
66.6 
(37.8, 110.7) 
64.2 
(33.4, 104.2) 
 
aTOC (µmol/L) 36.4 
(19.9, 67.0) 
23.4 
(14.5, 37.8) 
37.8 
(20.5, 74.7) 
36.7 
(23.5, 77.3) 
46.3 
(26.1, 89.3) 
28.8 
(18.4, 49.1) 
41.5 
(24.5, 67.1) 
32.0 
(20.9, 48.8) 
33.5 
(21.8, 52.1) 
34.8 
(22.9, 62.6) 
32.1 
(20.8, 65.1) 
 
gTOC (µmol/L) 2.48 
(0.61, 8.13) 
6.45 
(2.80, 13.46) 
3.60 
(0.81, 10.92) 
3.99 
(1.08, 9.76) 
3.48 
(1.02, 10.57) 
5.81 
(2.31, 10.96) 
2.38 
(0.72, 7.41) 
5.90 
(2.57, 11.27) 
5.15 
(1.59, 10.00) 
4.65 
(1.27, 10.32) 
3.62 
(1.17, 8.01) 
One-carbon metabolites  
          
 
tMet (µmol/L) 22.7 
(18.2, 28.1) 
24.9 
(15.6, 42.5) 
27.0 
(18.4, 41.1) 
27.0 
(19.3, 45.7) 
28.2 
(18.6, 50.2) 
29.0 
(20.2, 46.9) 
28.9 
(21.8, 36.7) 
25.7 
(19.2, 34.6) 
27.1 
(20.6, 36.2) 
27.1 
(19.3, 37.5) 
25.9 
(19.0, 33.3) 
 
tHcy (µmol/L) 7.3 
(5.0, 11.6) 
14.4 
(8.4, 24.7) 
9.8 
(6.2, 15.3) 
9.8 
(6.3, 15.9) 
13.1 
(8.3, 19.5) 
11.4 
(7.6, 18.9) 
10.4 
(7.0, 17.0) 
12.1 
(7.9, 22.5) 
12.1 
(8.0, 19.6) 
13.7 
(9.0, 20.9) 
11.8 
(8.5, 17.8) 
 
Cysta (µmol/L) 0.120 
(0.066, 0.227) 
0.189 
(0.083, 0.462) 
0.196 
(0.094, 0.440) 
0.177 
(0.091, 0.365) 
0.212 
(0.102, 0.494) 
0.216 
(0.106, 0.479) 
0.184 
(0.104, 0.336) 
0.151 
(0.084, 0.310) 
0.170 
(0.092, 0.352) 
0.188 
(0.104, 0.365) 
0.178 
(0.114, 0.324) 
 
tCys (µmol/L) 273 
(226, 332) 
283 
(216, 382) 
307 
(237, 386) 
290 
(241, 348) 
341 
(270, 424) 
310 
(258, 381) 
329 
(282, 402) 
303 
(236, 396) 
318 
(257, 386) 
308 
(245, 368) 
294 
(249, 358) 
 
Serine (µmol/L) 81.6 
(58.7, 116.9) 
104.0 
(74.4, 149.3) 
121.7 
(90.2, 164.1) 
147.1 
(113.4, 186.6) 
95.5 
(62.9, 134.6) 
111.2 
(75.9, 179.9) 
99.3 
(76.0, 133.6) 
107.7 
(75.6, 159.6) 
118.8 
(87.2, 165.4) 
98.0 
(70.6, 135.9) 
88.0 
(62.6, 118.6) 
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Glycine (µmol/L) 215 
(133, 391) 
248 
(163, 395) 
279 
(196, 399) 
322 
(226, 525) 
242 
(160, 386) 
279 
(182, 454) 
253 
(176, 401) 
286 
(172, 508) 
300 
(195, 520) 
236 
(167, 339) 
231 
(163, 322) 
 
Choline (µmol/L) 8.3 
(6.0, 11.5) 
14.4 
(10.3, 20.7) 
12.3 
(8.3, 18.0) 
12.5 
(8.6, 17.8) 
14.9 
(10.4, 21.2) 
14.3 
(10.0, 20.3) 
11.5 
(8.7, 15.6) 
11.8 
(8.6, 17.6) 
15.1 
(10.7, 22.5) 
13.1 
(9.1, 18.8) 
11.8 
(8.9, 16.9) 
 
Betaine (µmol/L) 24.2 
(12.7, 42.9) 
44.3 
(28.7, 73.5) 
37.6 
(18.8, 61.9) 
37.6 
(24.4, 59.7) 
40.5 
(18.9, 73.7) 
40.6 
(24.9, 64.7) 
40.2 
(25.0, 64.6) 
31.4 
(16.5, 54.6) 
30.8 
(17.4, 49.9) 
40.6 
(26.8, 61.3) 
39.7 
(25.9, 60.5) 
 
DMG (µmol/L) 2.45 
(1.44, 4.48) 
4.43 
(2.68, 9.12) 
3.56 
(1.92, 6.07) 
3.41 
(1.96, 7.00) 
4.30 
(2.45, 7.55) 
4.10 
(2.50, 6.80) 
3.60 
(1.92, 6.28) 
3.17 
(1.99, 5.27) 
2.91 
(1.75, 5.12) 
3.88 
(2.35, 6.42) 
3.76 
(2.42, 6.94) 
Tryptophan + metabolites  
          
 
Trp (µmol/L) 50.6 
(36.4, 63.7) 
54.3 
(37.7, 75.9) 
64.2 
(43.1, 91.3) 
65.9 
(46.3, 90.5) 
71.8 
(48.3, 103.2) 
66.8 
(44.6, 93.6) 
67.1 
(49.9, 88.3) 
68.1 
(51.8, 87.2) 
68.4 
(48.3, 91.2) 
67.0 
(47.7, 88.1) 
63.5 
(49.2, 80.4) 
 
Kyn (µmol/L) 1.29 
(0.92, 1.85) 
1.25 
(0.88, 1.92) 
1.66 
(1.06, 2.60) 
1.50 
(1.08, 2.15) 
1.79 
(1.28, 2.46) 
1.56 
(1.08, 2.21) 
1.66 
(1.19, 2.35) 
1.51 
(1.08, 2.09) 
1.53 
(1.08, 2.20) 
1.64 
(1.15, 2.39) 
1.59 
(1.15, 2.04) 
 
KA (nmol/L) 31.9 
(18.2, 58.7) 
35.5 
(13.9, 78.4) 
47.9 
(23.7, 102.9) 
41.6 
(22.5, 80.5) 
55.1 
(25.0, 117.2) 
43.4 
(22.2, 85.0) 
54.3 
(29.6, 105.2) 
41.6 
(21.0, 83.3) 
42.8 
(22.5, 78.6) 
53.0 
(28.2, 95.4) 
57.1 
(33.3, 98.4) 
 
AA (nmol/L) 13.9 
(7.6, 28.2) 
14.7 
(7.5, 42.2) 
14.7 
(7.8, 26.5) 
12.8 
(7.5, 23.3) 
15.9 
(9.7, 27.1) 
13.0 
(7.7, 23.9) 
16.9 
(10.5, 32.9) 
13.0 
(7.9, 23.0) 
15.6 
(8.9, 30.3) 
15.2 
(8.6, 27.1) 
18.4 
(10.3, 30.9) 
 
HK (nmol/L) 30.3 
(18.9, 54.5) 
29.8 
(14.5, 77.9) 
39.8 
(22.6, 71.9) 
36.6 
(23.7, 65.7) 
34.6 
(17.9, 63.0) 
37.9 
(21.4, 63.9) 
39.1 
(25.7, 64.5) 
32.8 
(16.4, 62.9) 
36.5 
(21.6, 66.9) 
30.4 
(16.1, 53.3) 
30.8 
(15.8, 48.7) 
 
XA (nmol/L) 7.2 
(2.4, 14.7) 
8.6 
(2.6, 24.1) 
12.1 
(4.5, 31.4) 
11.7 
(5.4, 31.8) 
15.8 
(6.5, 34.1) 
12.3 
(4.8, 29.4) 
11.7 
(4.2, 25.0) 
12.8 
(4.9, 36.0) 
11.6 
(4.7, 28.0) 
14.9 
(7.2, 29.1) 
13.4 
(6.4, 26.6) 
 
HAA (nmol/L) 26.1 
(15.7, 47.2) 
19.3 
(9.2, 44.3) 
35.2 
(18.8, 71.6) 
33.6 
(18.6, 58.7) 
42.1 
(23.2, 82.4) 
35.8 
(20.0, 66.0) 
35.9 
(20.8, 58.8) 
24.4 
(12.5, 50.5) 
30.3 
(16.4, 54.3) 
25.2 
(14.3, 45.6) 
27.7 
(15.0, 43.9) 
 
QA (nmol/L) 324 
(198, 628) 
342 
(172, 844) 
434 
(229, 809) 
336 
(210, 612) 
458 
(280, 778) 
364 
(204, 708) 
399 
(241, 743) 
370 
(219, 641) 
357 
(208, 710) 
372 
(224, 677) 
401 
(256, 690) 
Other  
           
 
CRP (µg/L) 2.23 
(0.30, 13.18) 
2.67 
(0.30, 16.09) 
2.08 
(0.24, 14.37) 
1.49 
(0.15, 10.97) 
3.03 
(0.46, 17.05) 
2.39 
(0.36, 15.19) 
1.54 
(0.23, 13.03) 
2.46 
(0.32, 13.13) 
2.72 
(0.39, 15.89) 
2.75 
(0.48, 15.36) 
1.26 
(0.28 ,5.77) 
 
KTR (nmol/µmol) 25.5 
(18.1, 39.6) 
23.1 
(15.6, 40.0) 
25.9 
(18.5, 40.0) 
22.7 
(16.2, 32.9) 
24.9 
(16.5, 38.4) 
23.4 
(16.9, 36.2) 
24.7 
(17.9, 35.8) 
22.1 
(16.1, 30.4) 
22.3 
(15.7, 35.4) 
24.4 
(16.8, 35.3) 
25.0 
(17.0, 35.7) 
 
PAr (PA/(PLP+PL)) 0.51 
(0.24, 1.00) 
0.49 
(0.14, 0.97) 
0.65 
(0.28, 1.25) 
0.54 
(0.24, 1.02) 
0.81 
(0.27, 1.83) 
0.49 
(0.21, 0.89) 
0.52 
(0.23, 1.05) 
0.53 
(0.23, 0.99) 
0.61 
(0.26, 1.21) 
0.60 
(0.28, 1.09) 
0.61 
(0.28, 1.39) 
 
Creat (µmol/L) 59.0 
(44.1, 79.2) 
84.8 
(59.5, 136.5) 
76.1 
(54.5, 102.0) 
64.8 
(48.4, 84.3) 
82.6 
(58.6, 120.0) 
80.0 
(57.6, 115.4) 
83.6 
(55.6, 123.0) 
69.7 
(53.0, 92.9) 
69.6 
(51.4, 93.5) 
87.9 
(67.0, 119.3) 
84.5 
(68.1, 107.0) 
 
HK/XA 5.13 
(1.94, 12.85) 
4.64 
(1.40, 10.97) 
3.76 
(1.32, 8.06) 
3.49 
(1.40, 6.55) 
2.48 
(0.99, 4.74) 
3.59 
(1.51, 7.01) 
3.87 
(1.75, 9.07) 
3.08 
(1.11, 8.27) 
3.87 
(1.36, 8.54) 
2.28 
(0.96, 3.87) 
2.58 
(1.09, 4.46) 
 
Cotinine (nmol/L) 0 
(0, 2) 
344 
(2, 2629) 
9 
(0, 1413) 
33 
(0, 1982) 
5 
(0, 1623) 
60 
(0, 2140) 
3 
(0, 1198) 
32 
(0, 1244) 
77 
(0, 2219) 
12 
(0, 1875) 
3 
(0, 1000) 
 
Arginine (µmol/L) 57.7 
(37.6, 85.3) 
31.9 
(10.5, 89.5) 
98.5 
(64.8, 139.0) 
109.1 
(79.6, 147.5) 
51.2 
(24.1, 101.9) 
84.7 
(55.7, 122.0) 
67.7 
(37.7, 108.4) 
44.2 
(14.9, 83.5) 
47.8 
(21.8, 90.1) 
30.9 
(10.9, 70.7) 
45.1 
(20.3, 76.4) 
 
ADMA (µmol/L) 0.456 
(0.339, 0.617) 
0.523 
(0.410, 0.718) 
0.505 
(0.380, 0.655) 
0.549 
(0.422, 0.672) 
0.549 
(0.438, 0.713) 
0.549 
(0.428, 0.687) 
0.563 
(0.434, 0.727) 
0.559 
(0.436, 0.713) 
0.560 
(0.442, 0.735) 
0.534 
(0.399, 0.713) 
0.521 
(0.403, 0.691) 
 
SDMA (µmol/L) 0.476 
(0.346, 0.737) 
0.582 
(0.401, 0.895) 
0.595 
(0.420, 0.830) 
0.578 
(0.424, 0.779) 
0.621 
(0.465, 0.836) 
0.585 
(0.436, 0.804) 
0.633 
(0.403, 1.053) 
0.540 
(0.397, 0.747) 
0.624 
(0.451, 0.883) 
0.480 
(0.346, 0.673) 
0.557 
(0.424, 0.739) 
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hArg (µmol/L) 1.53 
(0.78, 3.08) 
2.01 
(0.97, 3.83) 
1.68 
(0.88, 3.10) 
1.68 
(0.95, 3.60) 
1.97 
(1.00, 3.52) 
1.83 
(1.04, 3.40) 
1.93 
(0.96, 3.92) 
1.79 
(0.93, 3.70) 
1.66 
(0.92, 3.26) 
1.85 
(1.15, 2.89) 
1.81 
(1.00, 2.87) 
 
MMA (µmol/L) 0.172 
(0.111, 0.309) 
0.172 
(0.109, 0.315) 
0.180 
(0.110, 0.365) 
0.163 
(0.101, 0.283) 
0.211 
(0.131, 0.435) 
0.198 
(0.116, 0.350) 
0.176 
(0.100, 0.387) 
0.168 
(0.114, 0.275) 
0.166 
(0.103, 0.289) 
0.174 
(0.111, 0.305) 
0.171 
(0.110, 0.356) 
1CLUE, The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health 
Professionals Follow-up Study; MEC, The Multiethnic Cohort; NHS, The Nurses’ Health Study; NYUWHS, The New York University Women’s Health Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal and 
Ovarian  Cancer Screening Trial; SCCS, The Southern Community Cohort Study; WHI, The Women’s Health Initiative; WHS, Women’s Health Study. 
2AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; BVS, B-Vitamin Score; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; FVS, Fat-
soluble Vitamin Score; TOC, -tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine/tryptophan ratio; Kyn, kynurenine; MMA, methylmalonic acid; PA, 
4-pyridoxic acid; PAr, PLP/(PL+PA); PL, pyridoxal; PLP, pyridoxal 5'-phosphate; QA, quinolinic acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; tMet, total methionine; Trp, tryptophan; 
TVS, Total Vitamin Score; Vit A, all-trans retinol; Vit D, 25-OH vitamin D2 + season adjusted 25-OH vitamin D3; XA, xanthurenic acid. 
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SUPPLEMENTAL TABLE 4 
Crude geometric mean (5,95 percentiles) biomarker concentrations for Nordic, Asian and Australian cohorts1,2 
Region Nordic  Asian  Australia 
Cohort MDCS NSHDS ATBC HUNT  SCS SCHS SMHS SWHS  MCCS 
Number, n 198 244 200 193  513 379 421 416  353 
Vitamin scores 
    
 
    
 
 
 
TVS -0.04 
(-1.06, 1.10) 
-0.30 
(-1.20, 0.92) 
0.05 
(-1.26, 1.34) 
-0.15 
(-1.17, 0.86) 
 
-0.71 
(-1.73, 0.33) 
0.04 
(-1.20, 1.23) 
-0.77 
(-2.00, 0.52) 
-0.69 
(-1.78, 0.61) 
 
-0.01 
(-1.03, 0.99) 
 
BVS -0.39 
(-1.54, 0.95) 
-0.59 
(-1.71, 0.87) 
-0.19 
(-1.30, 1.04) 
-0.44 
(-1.63, 0.73) 
 
-0.41 
(-1.47, 0.75) 
-0.11 
(-1.55, 1.34) 
-0.58 
(-1.75, 0.91) 
-0.24 
(-1.24, 1.02) 
 
-0.27 
(-1.35, 0.94) 
 
FVS 0.38 
(-0.58, 1.29) 
0.13 
(-0.88, 1.04) 
0.33 
(-1.12, 1.94) 
0.24 
(-0.68, 1.19) 
 
-0.85 
(-2.02, 0.32) 
0.19 
(-0.79, 1.17) 
-0.77 
(-2.11, 0.57) 
-1.02 
(-2.26, 0.40) 
 
0.30 
(-0.81, 1.39) 
Vitamins 
    
 
    
 
 
 
B2 (nmol/L) 19.7 
(8.9, 60.2) 
10.4 
(3.9, 32.8) 
18.6 
(9.0, 44.9) 
19.3 
(8.8, 49.4) 
 
23.1 
(9.6, 75.0) 
23.5 
(7.5, 96.1) 
12.7 
(3.4, 71.9) 
14.2 
(4.3, 63.6) 
 
22.2 
(9.3, 62.8) 
 
PLP (nmol/L) 37.2 
(16.1, 132.0) 
32.9 
(14.2, 78.7) 
32.2 
(12.3, 104.4) 
28.2 
(12.1, 72.9) 
 
20.6 
(9.9, 48.6) 
37.4 
(12.4, 205.5) 
37.4 
(16.6, 106.6) 
43.3 
(19.7, 125.4) 
 
34.4 
(14.3, 110.4) 
 
PL (nmol/L) 23.3 
(10.8, 77.6) 
8.8 
(4.6, 17.9) 
16.1 
(8.2, 47.3) 
17.9 
(9.1, 48.2) 
 
15.3 
(6.9, 50.8) 
20.9 
(7.8, 142.3) 
9.0 
(4.0, 27.5) 
10.3 
(5.2, 29.7) 
 
17.8 
(9.2, 56.0) 
 
PA (nmol/L) 27.7 
(11.9, 124.3) 
19.9 
(10.8, 40.9) 
22.6 
(11.4, 62.7) 
21.5 
(10.2, 69.2) 
 
8.2 
(2.7, 29.2) 
23.1 
(8.8, 185.5) 
14.3 
(5.9, 62.0) 
14.4 
(6.2, 63.4) 
 
22.3 
(11.0, 72.0) 
 
Folate (nmol/L) 12.3 
(5.6, 44.0) 
9.1 
(4.3, 38.7) 
12.2 
(6.6, 25.8) 
9.4 
(4.7, 20.8) 
 
15.7 
(7.1, 37.1) 
15.8 
(7.2, 45.3) 
13.4 
(5.8, 39.2) 
16.5 
(7.6, 45.3) 
 
13.7 
(5.5, 35.2) 
 
B12 (pmol/L) 372 
(207, 674) 
507 
(287, 931) 
518 
(325, 823) 
468 
(272, 761) 
 
403 
(231, 681) 
415 
(210, 730) 
359 
(221, 585) 
420 
(271, 667) 
 
401 
(242, 659) 
 
Vit A (µmol/L) 2.30 
(1.66, 3.09) 
2.14 
(1.48, 2.85) 
2.52 
(1.78, 3.72) 
2.38 
(1.80, 3.12) 
 
1.82 
(1.23, 2.59) 
2.12 
(1.45, 3.12) 
1.89 
(1.21, 2.88) 
1.60 
(1.04, 2.39) 
 
2.29 
(1.60, 3.24) 
 
Vit D (nmol/L) 63.8 
(38.9, 96.3) 
56.6 
(32.9, 89.2) 
51.0 
(25.0, 104.8) 
62.4 
(35.3, 104.2) 
 
41.6 
(21.9, 71.8) 
64.8 
(44.1, 95.4) 
42.9 
(22.9, 75.6) 
39.0 
(21.7, 67.7) 
 
56.8 
(31.5, 97.4) 
 
aTOC (µmol/L) 33.1 
(23.5, 49.4) 
32.5 
(23.3, 45.8) 
33.6 
(20.6, 59.1) 
28.5 
(18.8, 43.0) 
 
22.7 
(16.2, 33.6) 
31.0 
(22.0, 45.3) 
22.5 
(14.6, 39.3) 
24.6 
(15.6, 41.5) 
 
34.4 
(23.3, 55.2) 
 
gTOC (µmol/L) 2.72 
(1.21, 5.72) 
2.56 
(1.30, 5.41) 
2.54 
(1.00, 5.90) 
4.94 
(2.36, 9.79) 
 
3.81 
(2.01, 7.04) 
1.65 
(0.78, 3.74) 
4.99 
(2.33, 9.69) 
6.21 
(2.71, 12.27) 
 
2.10 
(0.90, 5.05) 
One-carbon metabolites  
   
 
    
 
 
 
tMet (µmol/L) 25.8 
(17.8, 39.8) 
24.5 
(18.7, 31.9) 
27.8 
(20.8, 36.5) 
26.7 
(17.5, 41.5) 
 
30.1 
(20.7, 44.9) 
27.8 
(18.8, 40.9) 
26.2 
(17.7, 39.9) 
25.3 
(16.9, 40.2) 
 
26.8 
(19.6, 36.8) 
 
tHcy (µmol/L) 11.3 
(7.0, 20.9) 
9.8 
(6.1, 16.2) 
13.8 
(8.4, 21.8) 
12.4 
(7.7, 22.5) 
 
13.9 
(8.5, 32.6) 
14.9 
(9.1, 25.7) 
13.7 
(8.4, 32.9) 
9.4 
(6.2, 15.2) 
 
13.1 
(8.0, 22.0) 
 
Cysta (µmol/L) 0.214 
(0.118, 0.430) 
0.154 
(0.086, 0.364) 
0.173 
(0.103, 0.316) 
0.231 
(0.108, 0.573) 
 
0.283 
(0.154, 0.567) 
0.277 
(0.148, 0.591) 
0.269 
(0.142, 0.587) 
0.219 
(0.112, 0.485) 
 
0.195 
(0.111, 0.414) 
 
tCys (µmol/L) 286 
(226, 368) 
275 
(226, 327) 
338 
(259, 439) 
296 
(241, 362) 
 
275 
(222, 345) 
304 
(250, 367) 
273 
(219, 332) 
279 
(226, 330) 
 
304 
(253, 368) 
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Serine (µmol/L) 110.8 
(76.9, 158.4) 
104.6 
(79.2, 145.2) 
150.6 
(112.7, 195.0) 
177.7 
(140.7, 224.2) 
 
184.8 
(141.1, 248.6) 
125.8 
(93.0, 167.2) 
112.8 
(77.2, 157.7) 
118.4 
(84.2, 169.6) 
 
117.6 
(86.8, 158.1) 
 
Glycine (µmol/L) 238 
(160, 423) 
223 
(153, 385) 
283 
(212, 395) 
347 
(247, 521) 
 
359 
(273, 504) 
237 
(172, 342) 
247 
(173, 362) 
253 
(159, 433) 
 
250 
(178, 381) 
 
Choline (µmol/L) 11.7 
(8.1, 17.3) 
9.1 
(6.6, 12.7) 
12.9 
(8.9, 19.0) 
17.9 
(12.1, 28.3) 
 
20.9 
(13.3, 40.3) 
13.0 
(9.7, 17.3) 
12.3 
(8.7, 17.6) 
11.3 
(7.9, 15.9) 
 
14.7 
(9.6, 21.9) 
 
Betaine (µmol/L) 32.0 
(20.4, 55.3) 
29.7 
(18.7, 46.1) 
39.4 
(26.0, 61.0) 
33.7 
(20.7, 53.0) 
 
58.0 
(39.4, 86.9) 
45.0 
(29.1, 66.7) 
51.8 
(34.2, 76.1) 
48.7 
(32.5, 77.1) 
 
37.4 
(22.1, 59.3) 
 
DMG (µmol/L) 3.91 
(2.30, 7.22) 
3.79 
(2.34, 6.70) 
4.96 
(3.13, 7.76) 
4.19 
(2.54, 7.65) 
 
5.76 
(3.61, 10.01) 
4.87 
(2.96, 8.77) 
5.31 
(3.42, 9.01) 
4.68 
(2.85, 8.09) 
 
4.02 
(2.41, 7.10) 
Tryptophan + metabolites  
   
 
    
 
 
 
Trp (µmol/L) 63.9 
(46.0, 86.6) 
61.6 
(48.3, 77.0) 
76.0 
(57.6, 97.0) 
72.1 
(53.3, 95.4) 
 
75.0 
(55.9, 98.8) 
66.5 
(48.4, 86.8) 
63.9 
(47.9, 83.0) 
63.7 
(48.5, 83.9) 
 
68.3 
(52.3, 89.7) 
 
Kyn (µmol/L) 1.42 
(0.98, 2.15) 
1.42 
(1.01, 1.93) 
1.64 
(1.20, 2.23) 
1.62 
(1.18, 2.25) 
 
1.54 
(1.15, 2.16) 
1.62 
(1.17, 2.32) 
1.45 
(1.09, 2.01) 
1.40 
(1.02, 1.94) 
 
1.53 
(1.13, 2.17) 
 
KA (nmol/L) 36.2 
(21.2, 67.8) 
37.4 
(19.7, 70.3) 
41.3 
(24.2, 69.3) 
39.4 
(20.2, 70.9) 
 
47.2 
(23.4, 94.2) 
49.3 
(27.2, 111.3) 
44.9 
(23.2, 84.6) 
49.3 
(22.3, 100.7) 
 
46.2 
(26.1, 81.5) 
 
AA (nmol/L) 14.8 
(8.7, 29.1) 
12.5 
(7.6, 20.8) 
13.7 
(8.8, 23.2) 
18.3 
(10.2, 47.1) 
 
16.2 
(8.2, 50.3) 
14.4 
(7.7, 26.0) 
12.8 
(7.0, 21.9) 
12.2 
(7.8, 20.1) 
 
15.2 
(8.4, 30.6) 
 
HK (nmol/L) 33.1 
(19.8, 63.1) 
36.7 
(22.5, 62.7) 
41.6 
(26.2, 64.7) 
39.8 
(23.5, 67.1) 
 
47.1 
(24.5, 100.5) 
41.0 
(26.0, 77.4) 
35.4 
(20.1, 66.1) 
37.2 
(21.0, 68.3) 
 
36.7 
(22.3, 65.8) 
 
XA (nmol/L) 12.7 
(5.7, 28.7) 
10.6 
(4.4, 23.6) 
10.5 
(5.3, 23.5) 
14.4 
(6.7, 27.3) 
 
14.8 
(5.9, 33.1) 
13.1 
(6.0, 28.7) 
12.3 
(5.2, 28.9) 
11.8 
(4.9, 26.5) 
 
12.2 
(4.9, 26.5) 
 
HAA (nmol/L) 36.5 
(20.1, 63.0) 
30.3 
(18.6, 52.4) 
35.3 
(21.7, 58.7) 
32.8 
(17.2, 57.0) 
 
32.9 
(17.3, 64.2) 
35.6 
(20.2, 57.5) 
32.8 
(17.8, 56.2) 
34.2 
(19.0, 59.8) 
 
31.3 
(17.4, 53.2) 
 
QA (nmol/L) 332 
(198, 608) 
315 
(195, 559) 
368 
(235, 591) 
334 
(191, 723) 
 
332 
(203, 543) 
377 
(227, 689) 
354 
(208, 638) 
373 
(241, 598) 
 
356 
(222, 598) 
Other  
    
 
    
 
 
 
CRP (µg/L) 1.36 
(0.28, 8.06) 
1.52 
(0.19, 11.08) 
2.09 
(0.31, 15.13) 
1.39 
(0.18, 9.22) 
 
0.83 
(0.12, 8.96) 
1.42 
(0.26, 9.03) 
1.63 
(0.28, 13.38) 
1.53 
(0.23, 11.74) 
 
2.14 
(0.37, 11.78) 
 
KTR (nmol/µmol) 22.3 
(15.8, 33.8) 
23.0 
(17.2, 33.1) 
21.6 
(16.4, 27.5) 
22.4 
(16.5, 32.4) 
 
20.6 
(15.3, 28.8) 
24.3 
(17.6, 35.8) 
22.7 
(16.6, 32.4) 
21.9 
(16.2, 30.5) 
 
22.4 
(16.0, 31.6) 
 
PAr (PA/(PLP+PL)) 0.49 
(0.21, 0.92) 
0.51 
(0.25, 0.92) 
0.49 
(0.26, 0.85) 
0.51 
(0.24, 1.05) 
 
0.28 
(0.07, 0.59) 
0.43 
(0.18, 0.84) 
0.35 
(0.13, 0.66) 
0.30 
(0.14, 0.56) 
 
0.47 
(0.22, 0.82) 
 
Creat (µmol/L) 73.3 
(53.9, 98.0) 
70.7 
(54.0, 91.5) 
80.1 
(63.3, 104.0) 
71.4 
(54.6, 94.9) 
 
84.9 
(64.0, 109.0) 
74.7 
(50.0, 115.2) 
80.7 
(64.4, 102.0) 
61.5 
(48.7, 76.2) 
 
73.2 
(52.6, 103.0) 
 
HK/XA 2.93 
(1.35, 5.79) 
4.02 
(1.86, 7.75) 
4.39 
(1.90, 7.84) 
3.19 
(1.47, 6.04) 
 
3.87 
(1.42, 7.93) 
3.59 
(1.70, 7.44) 
3.71 
(1.49, 6.14) 
3.56 
(1.57, 6.62) 
 
3.36 
(1.46, 6.69) 
 
Cotinine (nmol/L) 28 
(0, 2066) 
135 
(1, 1645) 
782 
(218, 1577) 
187 
(2, 1634) 
 
390 
(5, 2082) 
61 
(0, 1863) 
187 
(2, 1680) 
6 
(1, 551) 
 
47 
(0, 2070) 
 
Arginine (µmol/L) 78.3 
(50.8, 114.4) 
66.6 
(42.7, 95.9) 
133.8 
(90.6, 193.1) 
136.4 
(103.0, 181.2) 
 
107.3 
(62.0, 169.1) 
70.3 
(43.1, 108.1) 
71.0 
(35.9, 118.0) 
79.3 
(49.1, 125.2) 
 
66.5 
(37.9, 107.4) 
 
ADMA (µmol/L) 0.540 
(0.408, 0.725) 
0.521 
(0.417, 0.625) 
0.589 
(0.466, 0.756) 
0.554 
(0.436, 0.706) 
 
0.584 
(0.440, 0.785) 
0.587 
(0.475, 0.739) 
0.535 
(0.415, 0.688) 
0.550 
(0.437, 0.692) 
 
0.546 
(0.430, 0.684) 
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SDMA (µmol/L) 0.545 
(0.387, 0.753) 
0.532 
(0.427, 0.692) 
0.644 
(0.478, 0.901) 
0.555 
(0.412, 0.756) 
 
0.706 
(0.516, 0.994) 
0.646 
(0.455, 0.981) 
0.613 
(0.458, 0.862) 
0.542 
(0.398, 0.736) 
 
0.588 
(0.448, 0.786) 
 
hArg (µmol/L) 1.70 
(1.03, 2.87) 
1.62 
(0.84, 2.95) 
2.11 
(1.18, 3.66) 
1.77 
(0.91, 3.23) 
 
2.27 
(1.32, 3.95) 
2.47 
(1.35, 4.20) 
2.39 
(1.35, 4.30) 
2.22 
(1.15, 3.87) 
 
2.01 
(1.11, 3.50) 
 
MMA (µmol/L) 0.189 
(0.111, 0.412) 
0.140 
(0.095, 0.216) 
0.157 
(0.101, 0.275) 
0.183 
(0.111, 0.310) 
 
0.192 
(0.110, 0.404) 
0.243 
(0.115, 0.701) 
0.197 
(0.102, 0.485) 
0.175 
(0.099, 0.359) 
 
0.173 
(0.108, 0.317) 
1ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; HUNT, The Nord-Trøndelag Health Study; MCCS, The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer Study; NSHDS, The 
Northern Sweden Health and Disease Study Cohort; SCHS, The Singapore Chinese Health Study; SCS, The Shanghai Cohort Study; SMHS, The Shanghai Men’s Health Study; SWHS, The Shanghai Women’s Health Study. 
2AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; BVS, B-Vitamin Score; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; FVS, Fat-
soluble Vitamin Score; TOC, -tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine/tryptophan ratio; Kyn, kynurenine; MMA, methylmalonic acid; PA, 
4-pyridoxic acid; PAr, PLP/(PL+PA); PL, pyridoxal; PLP, pyridoxal 5'-phosphate; QA, quinolinic acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; tMet, total methionine; Trp, tryptophan; 
TVS, Total Vitamin Score; Vit A, all-trans retinol; Vit D, 25-OH vitamin D2 + season adjusted 25-OH vitamin D3; XA, xanthurenic acid. 
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SUPPLEMENTAL TABLE 5 
Geometric mean biomarker concentrations (95% CI) for US cohorts from generalized linear models1,2,3 
Cohort 
 
WHI SCCS PLCO NYUWHS CPS-II CLUE MEC WHS NHS HPFS PHS 
Number, n 241 226 450 171 182 191 174 181 345 155 81 
Vitamin scores 
           
 TVS 0.10 
(-0.03 ,0.22) 
-0.34 
(-0.45 ,-0.23) 
0.43 
(0.35 ,0.51) 
0.73 
(0.59 ,0.86) 
1.14 
(1.02 ,1.27) 
0.24 
(0.11 ,0.36) 
0.95 
(0.83 ,1.08) 
0.10 
(-0.02 ,0.23) 
0.38 
(0.28 ,0.48) 
0.25 
(0.11 ,0.40) 
0.21 
(0.03 ,0.40) 
 BVS 0.17 
(0.04 ,0.29) 
0.02 
(-0.09 ,0.14) 
0.55 
(0.46 ,0.63) 
0.71 
(0.57 ,0.85) 
0.93 
(0.80 ,1.06) 
0.22 
(0.10 ,0.35) 
0.91 
(0.78 ,1.04) 
-0.11 
(-0.25 ,0.02) 
0.21 
(0.11 ,0.32) 
0.09 
(-0.06 ,0.24) 
0.02 
(-0.17 ,0.21) 
 FVS 0.03 
(-0.08, 0.15) 
-0.81 
(-0.91, -0.70) 
0.24 
(0.16, 0.32) 
0.50 
(0.38, 0.63) 
1.11 
(0.99, 1.23) 
0.06 
(-0.06, 0.18) 
0.72 
(0.60, 0.85) 
0.32 
(0.20, 0.44) 
0.42 
(0.32, 0.51) 
0.44 
(0.30, 0.58) 
0.36 
(0.19, 0.54) 
Vitamins 
           
 B2 (nmol/L) 19.2 
(17.2, 21.4) 
17.0 
(15.4, 18.8) 
26.9 
(25.0, 29.0) 
35.3 
(31.4, 39.7) 
29.9 
(26.8, 33.4) 
26.3 
(23.6, 29.3) 
21.8 
(19.5, 24.4) 
13.7 
(12.2, 15.3) 
27.6 
(25.3, 30.1) 
16.4 
(14.4, 18.7) 
14.5 
(12.3, 17.1) 
 PLP (nmol/L) 48.3 
(43.6, 53.6) 
43.7 
(39.7, 48.1) 
46.4 
(43.3, 49.7) 
61.8 
(55.2, 69.2) 
94.5 
(84.9, 105.1) 
44.5 
(40.0, 49.4) 
76.8 
(68.9, 85.7) 
51.0 
(45.8, 56.9) 
43.2 
(39.7, 46.9) 
63.7 
(56.2, 72.2) 
54.3 
(46.4, 63.6) 
 PL (nmol/L) 21.0 
(18.4, 23.9) 
6.3 
(5.6, 7.1) 
32.8 
(30.1, 35.8) 
38.8 
(33.7, 44.7) 
23.2 
(20.3, 26.5) 
29.3 
(25.7, 33.4) 
37.7 
(32.9, 43.2) 
10.0 
(8.7, 11.5) 
23.9 
(21.5, 26.5) 
14.2 
(12.2, 16.7) 
12.1 
(9.9, 14.7) 
 PA (nmol/L) 30.7 
(26.9, 34.9) 
19.1 
(17.0, 21.5) 
44.2 
(40.5, 48.1) 
55.2 
(48.0, 63.5) 
76.2 
(66.8, 87.0) 
33.5 
(29.4, 38.2) 
47.2 
(41.2, 54.0) 
31.2 
(27.2, 35.7) 
38.0 
(34.3, 42.2) 
43.4 
(37.2, 50.7) 
33.8 
(27.8, 41.1) 
 Folate (nmol/L) 38.2 
(34.8, 41.8) 
21.6 
(19.9, 23.5) 
48.4 
(45.6, 51.5) 
27.1 
(24.5, 29.9) 
31.2 
(28.4, 34.2) 
22.8 
(20.8, 25.0) 
59.9 
(54.5, 65.9) 
18.1 
(16.4, 19.9) 
25.2 
(23.4, 27.1) 
21.6 
(19.4, 24.1) 
24.5 
(21.3, 28.1) 
 B12 (pmol/L) 360 
(339, 381) 
451 
(427, 475) 
424 
(408, 441) 
513 
(482, 546) 
542 
(511, 576) 
440 
(415, 467) 
499 
(469, 530) 
434 
(409, 461) 
411 
(393, 431) 
409 
(382, 439) 
411 
(376, 449) 
 Vit A (µmol/L) 2.06 
(1.99, 2.14) 
1.94 
(1.88, 2.01) 
2.04 
(1.99, 2.08) 
2.38 
(2.29, 2.47) 
2.66 
(2.56, 2.76) 
2.17 
(2.10, 2.25) 
2.29 
(2.21, 2.38) 
2.36 
(2.27, 2.45) 
2.38 
(2.32, 2.45) 
2.27 
(2.18, 2.37) 
2.41 
(2.28, 2.54) 
 Vit D (nmol/L) 53.7 
(50.9, 56.7) 
36.0 
(34.3, 37.9) 
59.0 
(56.9, 61.2) 
62.4 
(58.8, 66.1) 
76.5 
(72.4, 80.8) 
59.7 
(56.5, 63.0) 
74.0 
(70.0, 78.4) 
62.3 
(58.9, 65.9) 
64.8 
(62.0, 67.6) 
64.9 
(60.8, 69.2) 
61.3 
(56.5, 66.5) 
 aTOC (µmol/L) 33.1 
(31.6, 34.6) 
24.6 
(23.6, 25.6) 
37.0 
(36.0, 38.2) 
36.0 
(34.3, 37.8) 
43.8 
(41.9, 45.9) 
28.9 
(27.6, 30.2) 
39.5 
(37.7, 41.4) 
31.1 
(29.7, 32.6) 
32.3 
(31.2, 33.5) 
35.1 
(33.3, 37.0) 
31.9 
(29.8, 34.1) 
 gTOC (µmol/L) 2.64 
(2.43, 2.88) 
6.28 
(5.81, 6.78) 
3.60 
(3.40, 3.81) 
4.07 
(3.72, 4.46) 
3.56 
(3.27, 3.88) 
5.87 
(5.39, 6.39) 
2.40 
(2.20, 2.63) 
6.06 
(5.55, 6.62) 
5.31 
(4.96, 5.68) 
4.67 
(4.22, 5.17) 
3.56 
(3.14, 4.05) 
One-carbon metabolites  
           
 tMet (µmol/L) 24.8 
(24.0, 25.6) 
25.7 
(24.9, 26.5) 
27.7 
(27.1, 28.3) 
29.2 
(28.2, 30.2) 
30.1 
(29.1, 31.1) 
29.9 
(29.0, 30.9) 
29.9 
(28.9, 31.0) 
27.7 
(26.8, 28.7) 
29.3 
(28.5, 30.1) 
26.7 
(25.7, 27.8) 
26.2 
(24.9, 27.5) 
 tHcy (µmol/L) 8.1 
(7.8, 8.5) 
14.4 
(13.8, 15.0) 
9.3 
(9.1, 9.6) 
11.2 
(10.6, 11.8) 
12.8 
(12.2, 13.4) 
11.3 
(10.8, 11.9) 
9.6 
(9.2, 10.1) 
13.5 
(12.8, 14.2) 
13.3 
(12.8, 13.8) 
12.6 
(11.9, 13.3) 
10.8 
(10.0, 11.5) 
 Cysta (µmol/L) 0.124 
(0.116. 0.132) 
0.198 
(0.187. 0.210) 
0.181 
(0.174. 0.190) 
0.202 
(0.188. 0.216) 
0.196 
(0.183. 0.210) 
0.217 
(0.203. 0.232) 
0.162 
(0.152. 0.174) 
0.168 
(0.157. 0.179) 
0.184 
(0.175. 0.194) 
0.170 
(0.158. 0.184) 
0.157 
(0.143. 0.174) 
 tCys (µmol/L) 262 
(257, 267) 
295 
(290, 300) 
295 
(291, 299) 
305 
(299, 311) 
323 
(317, 330) 
315 
(309, 321) 
307 
(301, 313) 
314 
(308, 320) 
327 
(322, 332) 
297 
(290, 304) 
277 
(269, 285) 
 Serine (µmol/L) 82 
(80, 84) 
103 
(100, 105) 
124 
(122, 127) 
144 
(139, 148) 
98 
(95, 101) 
107 
(104, 110) 
102 
(99, 106) 
106 
(102, 109) 
117 
(115, 120) 
100 
(96, 103) 
91 
(87, 95) 
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 Glycine (µmol/L) 207 
(199, 215) 
248 
(240, 257) 
286 
(279, 294) 
309 
(297, 322) 
243 
(234, 252) 
274 
(264, 284) 
257 
(247, 267) 
273 
(262, 283) 
286 
(278, 295) 
247 
(236, 259) 
245 
(232, 259) 
 Choline (µmol/L) 8.6 
(8.3, 8.9) 
14.6 
(14.2, 15.1) 
11.9 
(11.6, 12.1) 
13.2 
(12.7, 13.7) 
14.5 
(14.0, 15.0) 
13.9 
(13.4, 14.4) 
11.0 
(10.6, 11.4) 
12.4 
(11.9, 12.8) 
15.7 
(15.2, 16.1) 
12.4 
(11.9, 12.9) 
11.2 
(10.6, 11.8) 
 Betaine (µmol/L) 26.6 
(25.5, 27.7) 
44.2 
(42.5, 46.0) 
35.9 
(34.9, 36.9) 
44.3 
(42.4, 46.4) 
40.3 
(38.6, 42.1) 
41.2 
(39.4, 42.9) 
38.0 
(36.4, 39.7) 
36.7 
(35.1, 38.4) 
35.4 
(34.3, 36.7) 
35.5 
(33.7, 37.3) 
34.6 
(32.5, 36.9) 
 DMG (µmol/L) 2.66 
(2.54, 2.79) 
4.45 
(4.25, 4.65) 
3.41 
(3.30, 3.52) 
3.94 
(3.74, 4.16) 
4.24 
(4.04, 4.46) 
4.22 
(4.02, 4.43) 
3.35 
(3.19, 3.53) 
3.65 
(3.47, 3.84) 
3.29 
(3.17, 3.42) 
3.46 
(3.26, 3.67) 
3.35 
(3.11, 3.61) 
Tryptophan + metabolites  
           
 Trp (µmol/L) 53.9 
(52.5, 55.4) 
53.2 
(51.9, 54.6) 
63.9 
(62.7, 65.1) 
68.6 
(66.5, 70.6) 
73.6 
(71.5, 75.7) 
65.9 
(64.1, 67.7) 
67.8 
(65.9, 69.8) 
71.1 
(69.1, 73.1) 
71.8 
(70.2, 73.4) 
64.3 
(62.2, 66.4) 
61.4 
(58.9, 64.0) 
 Kyn (µmol/L) 1.30 
(1.26, 1.34) 
1.30 
(1.27, 1.34) 
1.57 
(1.53, 1.60) 
1.60 
(1.55, 1.66) 
1.68 
(1.63, 1.73) 
1.57 
(1.52, 1.62) 
1.52 
(1.48, 1.57) 
1.60 
(1.55, 1.65) 
1.60 
(1.56, 1.64) 
1.52 
(1.47, 1.58) 
1.44 
(1.38, 1.51) 
 KA (nmol/L) 32.5 
(30.5, 34.5) 
37.3 
(35.2, 39.4) 
43.9 
(42.2, 45.8) 
46.5 
(43.5, 49.7) 
51.2 
(48.1, 54.6) 
43.6 
(41.0, 46.4) 
48.7 
(45.7, 52.0) 
45.9 
(43.1, 49.0) 
46.8 
(44.5, 49.1) 
46.9 
(43.5, 50.5) 
49.1 
(44.8, 54.0) 
 AA (nmol/L) 13.0 
(12.2, 13.8) 
16.0 
(15.1, 16.9) 
13.5 
(12.9, 14.0) 
13.9 
(13.0, 14.8) 
14.4 
(13.5, 15.3) 
12.7 
(12.0, 13.5) 
14.9 
(14.0, 15.9) 
13.8 
(13.0, 14.7) 
16.5 
(15.7, 17.3) 
14.0 
(13.0, 15.0) 
16.0 
(14.6, 17.5) 
 HK (nmol/L) 29.6 
(28.1, 31.3) 
30.9 
(29.4, 32.5) 
38.0 
(36.7, 39.4) 
37.3 
(35.2, 39.5) 
32.6 
(30.9, 34.5) 
38.2 
(36.2, 40.4) 
36.4 
(34.4, 38.5) 
33.1 
(31.3, 35.0) 
36.7 
(35.2, 38.4) 
29.3 
(27.4, 31.2) 
29.2 
(26.9, 31.7) 
 XA (nmol/L) 7.9 
(7.3, 8.5) 
8.5 
(7.9, 9.1) 
11.7 
(11.1, 12.3) 
12.3 
(11.2, 13.4) 
15.9 
(14.6, 17.3) 
12.0 
(11.0, 13.0) 
11.6 
(10.7, 12.7) 
13.6 
(12.4, 14.8) 
12.4 
(11.6, 13.2) 
13.8 
(12.5, 15.2) 
12.4 
(11.0, 14.1) 
 HAA (nmol/L) 27.6 
(26.1, 29.2) 
19.2 
(18.2, 20.2) 
33.8 
(32.6, 35.1) 
35.5 
(33.4, 37.7) 
42.0 
(39.7, 44.5) 
35.7 
(33.7, 37.8) 
35.2 
(33.2, 37.4) 
26.0 
(24.5, 27.6) 
32.8 
(31.3, 34.3) 
23.2 
(21.6, 24.8) 
25.3 
(23.3, 27.6) 
 QA (nmol/L) 293 
(279, 308) 
383 
(366, 401) 
387 
(374, 401) 
363 
(344, 384) 
397 
(377, 417) 
370 
(351, 389) 
337 
(320, 355) 
391 
(371, 412) 
372 
(357, 387) 
340 
(320, 361) 
342 
(317, 369) 
Other  
           
 CRP (µg/L) 2.05 
(1.73, 2.43) 
2.97 
(2.54, 3.47) 
1.98 
(1.77, 2.22) 
1.48 
(1.23, 1.79) 
2.64 
(2.22, 3.15) 
2.54 
(2.14, 3.02) 
1.32 
(1.10, 1.58) 
2.35 
(1.97, 2.82) 
2.46 
(2.14, 2.82) 
2.90 
(2.36, 3.56) 
1.31 
(1.01, 1.70) 
 KTR (nmol/µmol) 24.2 
(23.4, 25.0) 
24.5 
(23.8, 25.2) 
24.5 
(24.0, 25.1) 
23.4 
(22.5, 24.2) 
22.9 
(22.1, 23.6) 
23.8 
(23.0, 24.6) 
22.5 
(21.7, 23.3) 
22.5 
(21.7, 23.3) 
22.3 
(21.8, 22.9) 
23.7 
(22.8, 24.7) 
23.5 
(22.3, 24.7) 
 PAr (PA/(PLP+PL)) 0.435 
(0.405, 0.467) 
0.370 
(0.347, 0.396) 
0.536 
(0.511, 0.563) 
0.517 
(0.478, 0.559) 
0.608 
(0.564, 0.655) 
0.443 
(0.412, 0.476) 
0.405 
(0.375, 0.436) 
0.504 
(0.467, 0.544) 
0.546 
(0.516, 0.579) 
0.527 
(0.484, 0.575) 
0.499 
(0.447, 0.557) 
 Creat (µmol/L) 64.0 
(62.3, 65.8) 
85.1 
(83.0, 87.3) 
71.9 
(70.6, 73.2) 
73.5 
(71.3, 75.7) 
81.1 
(78.9, 83.4) 
80.0 
(77.8, 82.2) 
78.7 
(76.5, 81.0) 
78.4 
(76.2, 80.6) 
78.3 
(76.6, 80.0) 
78.3 
(75.7, 80.9) 
74.5 
(71.5, 77.7) 
 HK/XA 3.76 
(3.49, 4.06) 
3.65 
(3.41, 3.91) 
3.26 
(3.10, 3.42) 
3.04 
(2.80, 3.30) 
2.05 
(1.90, 2.21) 
3.20 
(2.96, 3.45) 
3.13 
(2.90, 3.39) 
2.44 
(2.26, 2.64) 
2.97 
(2.79, 3.15) 
2.12 
(1.94, 2.32) 
2.35 
(2.10, 2.64) 
 Cotinine (nmol/L) 20 
(16, 24) 
83 
(69, 100) 
30 
(26, 34) 
48 
(38, 59) 
26 
(21, 32) 
60 
(49, 73) 
12 
(10, 15) 
40 
(32, 49) 
70 
(60, 83) 
28 
(22, 35) 
20 
(15, 27) 
 Arginine (µmol/L) 58.4 
(55.4, 61.5) 
32.0 
(30.5, 33.5) 
98.0 
(94.7, 101.5) 
113.1 
(106.9, 119.8) 
51.1 
(48.5, 53.9) 
83.9 
(79.6, 88.4) 
66.6 
(63.0, 70.4) 
45.5 
(43.0, 48.0) 
49.0 
(47.0, 51.1) 
30.3 
(28.4, 32.2) 
44.2 
(40.9, 47.9) 
 ADMA (µmol/L) 0.454 
(0.443, 0.464) 
0.533 
(0.522, 0.544) 
0.497 
(0.489, 0.504) 
0.565 
(0.551, 0.579) 
0.536 
(0.524, 0.549) 
0.550 
(0.537, 0.563) 
0.543 
(0.530, 0.556) 
0.570 
(0.557, 0.584) 
0.566 
(0.556, 0.577) 
0.523 
(0.509, 0.538) 
0.509 
(0.491, 0.527) 
 SDMA (µmol/L) 0.468 
(0.454, 0.482) 
0.606 
(0.589, 0.624) 
0.566 
(0.555, 0.578) 
0.630 
(0.610, 0.652) 
0.585 
(0.567, 0.604) 
0.589 
(0.571, 0.607) 
0.581 
(0.562, 0.599) 
0.576 
(0.558, 0.595) 
0.657 
(0.641, 0.673) 
0.453 
(0.436, 0.470) 
0.512 
(0.489, 0.537) 
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 hArg (µmol/L) 1.63 
(1.54, 1.71) 
1.98 
(1.88, 2.07) 
1.64 
(1.59, 1.70) 
1.76 
(1.66, 1.87) 
2.02 
(1.92, 2.14) 
1.80 
(1.70, 1.90) 
1.96 
(1.86, 2.07) 
1.91 
(1.81, 2.02) 
1.81 
(1.73, 1.88) 
1.72 
(1.61, 1.83) 
1.67 
(1.54, 1.81) 
 MMA (µmol/L) 0.168 
(0.159, 0.178) 
0.182 
(0.172, 0.192) 
0.169 
(0.163, 0.176) 
0.175 
(0.165, 0.187) 
0.194 
(0.183, 0.206) 
0.201 
(0.189, 0.213) 
0.158 
(0.148, 0.168) 
0.176 
(0.166, 0.187) 
0.172 
(0.164, 0.180) 
0.167 
(0.156, 0.180) 
0.157 
(0.143, 0.171) 
1CLUE, The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health 
Professionals Follow-up Study; MEC, The Multiethnic Cohort; NHS, The Nurses’ Health Study; NYUWHS, The New York University Women’s Health Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal and 
Ovarian  Cancer Screening Trial; SCCS, The Southern Community Cohort Study; WHI, The Women’s Health Initiative; WHS, Women’s Health Study. 
2AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; BVS, B-Vitamin Score; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; FVS, Fat-
soluble Vitamin Score; TOC, -tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine/tryptophan ratio; Kyn, kynurenine; MMA, methylmalonic acid; PA, 
4-pyridoxic acid; PAr, PLP/(PL+PA); PL, pyridoxal; PLP, pyridoxal 5'-phosphate; QA, quinolinic acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; tMet, total methionine; Trp, tryptophan; 
TVS, Total Vitamin Score; Vit A, all-trans retinol; Vit D, 25-OH vitamin D2 + season adjusted 25-OH vitamin D3; XA, xanthurenic acid. 
3General linear models, adjusted for age, sex, smoking (former vs. never, current vs. never).  
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SUPPLEMENTAL TABLE 6 
Geometric mean biomarker concentrations (95% CI) for Nordic, Asian, Australian cohorts from generalized linear models1,2,3 
Region  Nordic  Asian  Australia 
Cohort 
 
MDCS NSHDS ATBC HUNT  SCS SCHS SMHS SWHS  MCCS 
Number, n 
 
198 244 200 193  513 379 421 416  353 
Vitamin scores 
    
 
    
 
 
 TVS -0.12 
(-0.24 ,0.00) 
-0.31 
(-0.42 ,-0.20) 
0.20 
(0.08 ,0.33) 
-0.07 
(-0.19 ,0.05) 
 
-0.43 
(-0.52 ,-0.34) 
0.01 
(-0.08 ,0.09) 
-0.61 
(-0.69 ,-0.52) 
-0.84 
(-0.93 ,-0.74) 
 
-0.05 
(-0.14 ,0.03) 
 BVS -0.42 
(-0.55 ,-0.30) 
-0.51 
(-0.62 ,-0.40) 
0.07 
(-0.06 ,0.19) 
-0.39 
(-0.52 ,-0.27) 
 
-0.16 
(-0.25 ,-0.07) 
-0.11 
(-0.20 ,-0.02) 
-0.43 
(-0.52 ,-0.34) 
-0.49 
(-0.59 ,-0.39) 
 
-0.23 
(-0.32 ,-0.13) 
 FVS 0.39 
(0.27, 0.50) 
0.19 
(0.09, 0.30) 
0.42 
(0.30, 0.53) 
0.28 
(0.17, 0.39) 
 
-0.73 
(-0.81, -0.65) 
0.14 
(0.06, 0.23) 
-0.74 
(-0.82, -0.66) 
-1.06 
(-1.15, -0.96) 
 
0.31 
(0.22, 0.39) 
Vitamins 
    
 
    
 
 
 B2 (nmol/L) 19.9 
(17.9, 22.1) 
11.2 
(10.2, 12.3) 
21.4 
(19.2, 23.9) 
20.5 
(18.4, 22.8) 
 
27.4 
(25.3, 29.6) 
22.6 
(20.9, 24.4) 
13.6 
(12.6, 14.7) 
12.8 
(11.8, 14.0) 
 
22.9 
(21.2, 24.8) 
 PLP (nmol/L) 35.9 
(32.4, 39.7) 
33.8 
(30.9, 37.1) 
38.3 
(34.5, 42.5) 
29.2 
(26.4, 32.3) 
 
23.4 
(21.7, 25.2) 
38.8 
(36.0, 41.8) 
41.0 
(38.1, 44.1) 
36.4 
(33.5, 39.6) 
 
34.5 
(32.0, 37.2) 
 PL (nmol/L) 22.5 
(19.9, 25.6) 
9.5 
(8.4, 10.6) 
19.3 
(17.0, 22.0) 
18.6 
(16.4, 21.2) 
 
18.3 
(16.7, 20.1) 
20.8 
(19.0, 22.9) 
9.9 
(9.1, 10.9) 
8.8 
(7.9, 9.8) 
 
18.2 
(16.5, 20.0) 
 PA (nmol/L) 27.3 
(24.1, 31.0) 
22.6 
(20.2, 25.3) 
27.2 
(23.9, 31.0) 
23.1 
(20.4, 26.2) 
 
10.0 
(9.1, 11.0) 
21.6 
(19.7, 23.7) 
15.4 
(14.1, 16.9) 
12.9 
(11.7, 14.3) 
 
23.4 
(21.4, 25.7) 
 Folate (nmol/L) 12.0 
(11.0, 13.2) 
9.7 
(9.0, 10.6) 
14.9 
(13.6, 16.3) 
9.8 
(8.9, 10.7) 
 
19.1 
(17.8, 20.4) 
15.8 
(14.8, 16.9) 
15.0 
(14.1, 16.0) 
13.8 
(12.9, 14.9) 
 
14.2 
(13.3, 15.2) 
 B12 (pmol/L) 370 
(350, 391) 
510 
(485, 537) 
542 
(512, 575) 
465 
(439, 492) 
 
422 
(405, 440) 
418 
(401, 435) 
372 
(357, 388) 
394 
(376, 413) 
 
406 
(390, 424) 
 Vit A (µmol/L) 2.31 
(2.24, 2.39) 
2.17 
(2.10, 2.23) 
2.49 
(2.41, 2.58) 
2.43 
(2.34, 2.51) 
 
1.81 
(1.77, 1.86) 
2.08 
(2.03, 2.13) 
1.86 
(1.81, 1.90) 
1.66 
(1.61, 1.70) 
 
2.28 
(2.22, 2.34) 
 Vit D (nmol/L) 64.1 
(60.9, 67.6) 
57.6 
(54.9, 60.4) 
52.8 
(50.0, 55.7) 
63.6 
(60.4, 67.1) 
 
42.9 
(41.3, 44.7) 
64.4 
(62.0, 67.0) 
43.3 
(41.7, 45.0) 
38.5 
(36.8, 40.1) 
 
56.8 
(54.7, 59.1) 
 aTOC (µmol/L) 33.1 
(31.7, 34.5) 
33.6 
(32.3, 34.9) 
36.1 
(34.6, 37.8) 
28.5 
(27.3, 29.7) 
 
24.8 
(24.0, 25.6) 
30.8 
(29.8, 31.8) 
23.7 
(22.9, 24.4) 
23.3 
(22.5, 24.1) 
 
34.9 
(33.8, 36.1) 
 gTOC (µmol/L) 2.72 
(2.51, 2.96) 
2.54 
(2.35, 2.73) 
2.44 
(2.24, 2.66) 
4.99 
(4.60, 5.42) 
 
3.64 
(3.43, 3.87) 
1.64 
(1.55, 1.75) 
4.83 
(4.55, 5.13) 
6.50 
(6.08, 6.95) 
 
2.08 
(1.95, 2.21) 
One-carbon metabolites  
    
 
    
 
 
 tMet (µmol/L) 27.7 
(26.9, 28.6) 
25.2 
(24.5, 26.0) 
27.8 
(27.0, 28.8) 
29.4 
(28.5, 30.4) 
 
31.8 
(31.1, 32.6) 
28.9 
(28.2, 29.6) 
26.7 
(26.1, 27.3) 
27.9 
(27.2, 28.6) 
 
27.4 
(26.8, 28.1) 
 tHcy (µmol/L) 11.7 
(11.2, 12.2) 
10.3 
(9.9, 10.7) 
12.3 
(11.8, 12.9) 
12.9 
(12.3, 13.5) 
 
12.7 
(12.3, 13.2) 
13.7 
(13.2, 14.1) 
12.4 
(12.0, 12.9) 
11.0 
(10.6, 11.4) 
 
13.2 
(12.8, 13.7) 
 Cysta (µmol/L) 0.221 
(0.208. 0.236) 
0.166 
(0.157. 0.176) 
0.164 
(0.154. 0.175) 
0.244 
(0.229. 0.260) 
 
0.278 
(0.265. 0.291) 
0.251 
(0.240. 0.263) 
0.250 
(0.239. 0.262) 
0.250 
(0.237. 0.263) 
 
0.200 
(0.191. 0.210) 
 tCys (µmol/L) 290 
(284, 295) 
287 
(282, 292) 
343 
(337, 350) 
305 
(299, 310) 
 
280 
(277, 284) 
292 
(288, 296) 
271 
(267, 274) 
283 
(279, 287) 
 
309 
(305, 314) 
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 Serine (µmol/L) 112 
(109, 115) 
103 
(101, 106) 
150 
(146, 154) 
175 
(171, 180) 
 
183 
(180, 187) 
128 
(125, 131) 
113 
(111, 116) 
116 
(114, 119) 
 
117 
(114, 119) 
 Glycine (µmol/L) 239 
(231, 248) 
223 
(215, 230) 
289 
(278, 300) 
339 
(327, 351) 
 
369 
(360, 379) 
240 
(233, 246) 
254 
(248, 261) 
243 
(236, 251) 
 
253 
(246, 260) 
 Choline (µmol/L) 11.7 
(11.3, 12.1) 
9.3 
(9.0, 9.6) 
12.5 
(12.1, 13.0) 
18.3 
(17.7, 18.9) 
 
20.4 
(19.9, 20.9) 
12.6 
(12.2, 12.9) 
11.8 
(11.5, 12.1) 
12.1 
(11.7, 12.4) 
 
14.6 
(14.3, 15.0) 
 Betaine (µmol/L) 33.1 
(31.8, 34.5) 
30.7 
(29.6, 31.9) 
35.2 
(33.8, 36.7) 
36.0 
(34.5, 37.5) 
 
52.2 
(50.7, 53.9) 
41.7 
(40.5, 43.0) 
45.9 
(44.5, 47.3) 
55.3 
(53.4, 57.1) 
 
37.1 
(36.0, 38.3) 
 DMG (µmol/L) 4.02 
(3.84, 4.22) 
3.96 
(3.79, 4.13) 
4.45 
(4.24, 4.67) 
4.42 
(4.21, 4.63) 
 
5.28 
(5.09, 5.46) 
4.48 
(4.33, 4.64) 
4.74 
(4.58, 4.90) 
5.35 
(5.15, 5.56) 
 
4.04 
(3.90, 4.18) 
Tryptophan + metabolites  
    
 
    
 
 
 Trp (µmol/L) 64.7 
(63.0, 66.4) 
61.0 
(59.5, 62.4) 
72.6 
(70.6, 74.6) 
73.3 
(71.4, 75.3) 
 
71.1 
(69.7, 72.5) 
66.0 
(64.7, 67.3) 
61.4 
(60.2, 62.6) 
66.7 
(65.3, 68.2) 
 
67.4 
(66.1, 68.8) 
 Kyn (µmol/L) 1.44 
(1.40, 1.48) 
1.48 
(1.44, 1.52) 
1.64 
(1.59, 1.69) 
1.68 
(1.64, 1.74) 
 
1.56 
(1.52, 1.59) 
1.54 
(1.51, 1.58) 
1.41 
(1.38, 1.44) 
1.49 
(1.45, 1.52) 
 
1.54 
(1.51, 1.57) 
 KA (nmol/L) 37.0 
(34.8, 39.3) 
39.6 
(37.5, 41.8) 
40.8 
(38.4, 43.4) 
42.0 
(39.6, 44.6) 
 
47.0 
(44.9, 49.1) 
46.1 
(44.1, 48.2) 
42.5 
(40.7, 44.4) 
53.5 
(51.0, 56.2) 
 
46.3 
(44.2, 48.4) 
 AA (nmol/L) 14.9 
(14.1, 15.8) 
13.3 
(12.6, 14.1) 
14.5 
(13.7, 15.4) 
19.2 
(18.1, 20.4) 
 
17.8 
(17.0, 18.6) 
13.6 
(13.0, 14.2) 
12.7 
(12.2, 13.3) 
12.4 
(11.8, 13.0) 
 
15.4 
(14.7, 16.1) 
 HK (nmol/L) 33.2 
(31.5, 35.0) 
38.0 
(36.2, 39.8) 
43.0 
(40.7, 45.3) 
40.6 
(38.5, 42.8) 
 
47.9 
(46.1, 49.8) 
39.8 
(38.3, 41.4) 
35.5 
(34.2, 36.9) 
38.1 
(36.5, 39.7) 
 
37.1 
(35.7, 38.6) 
 XA (nmol/L) 12.8 
(11.9, 13.9) 
10.4 
(9.7, 11.2) 
10.2 
(9.4, 11.0) 
14.9 
(13.8, 16.2) 
 
13.7 
(12.9, 14.5) 
13.0 
(12.3, 13.8) 
11.7 
(11.0, 12.4) 
12.5 
(11.8, 13.4) 
 
11.9 
(11.2, 12.6) 
 HAA (nmol/L) 37.1 
(35.2, 39.2) 
30.4 
(28.9, 31.9) 
34.4 
(32.6, 36.4) 
34.3 
(32.5, 36.2) 
 
31.5 
(30.2, 32.8) 
35.1 
(33.7, 36.5) 
31.4 
(30.1, 32.6) 
35.9 
(34.4, 37.6) 
 
30.8 
(29.6, 32.1) 
 QA (nmol/L) 334 
(318, 351) 
345 
(330, 361) 
402 
(383, 423) 
356 
(339, 374) 
 
367 
(354, 381) 
352 
(339, 364) 
359 
(346, 372) 
379 
(364, 394) 
 
365 
(352, 379) 
Other  
    
 
    
 
 
 CRP (µg/L) 1.38 
(1.17, 1.63) 
1.66 
(1.43, 1.93) 
2.15 
(1.81, 2.55) 
1.34 
(1.14, 1.59) 
 
0.93 
(0.82, 1.05) 
1.29 
(1.14, 1.46) 
1.68 
(1.49, 1.90) 
1.64 
(1.43, 1.88) 
 
2.28 
(2.02, 2.59) 
 KTR (nmol/µmol) 22.3 
(21.6, 23.0) 
24.3 
(23.6, 25.0) 
22.6 
(21.8, 23.3) 
23.0 
(22.3, 23.7) 
 
21.9 
(21.4, 22.4) 
23.4 
(22.8, 23.9) 
23.0 
(22.4, 23.5) 
22.3 
(21.7, 22.9) 
 
22.8 
(22.3, 23.4) 
 PAr (PA/(PLP+PL)) 0.458 
(0.427, 0.491) 
0.512 
(0.481, 0.546) 
0.462 
(0.430, 0.497) 
0.477 
(0.445, 0.512) 
 
0.231 
(0.219, 0.243) 
0.346 
(0.328, 0.364) 
0.296 
(0.281, 0.312) 
0.283 
(0.267, 0.300) 
 
0.437 
(0.415, 0.461) 
 Creat (µmol/L) 74.8 
(72.8, 76.8) 
72.8 
(71.1, 74.5) 
74.4 
(72.4, 76.4) 
75.6 
(73.6, 77.6) 
 
78.6 
(77.1, 80.2) 
70.4 
(69.1, 71.8) 
73.7 
(72.3, 75.2) 
68.8 
(67.4, 70.3) 
 
73.0 
(71.5, 74.4) 
 HK/XA 2.59 
(2.41, 2.78) 
3.64 
(3.41, 3.89) 
4.23 
(3.92, 4.56) 
2.72 
(2.53, 2.93) 
 
3.50 
(3.32, 3.70) 
3.05 
(2.89, 3.22) 
3.04 
(2.88, 3.21) 
3.03 
(2.86, 3.22) 
 
3.12 
(2.95, 3.29) 
 Cotinine (nmol/L) 42 
(35, 51) 
77 
(65, 92) 
48 
(39, 59) 
84 
(69, 103) 
 
42 
(36, 48) 
41 
(36, 48) 
49 
(42, 56) 
69 
(58, 81) 
 
47 
(41, 54) 
 Arginine (µmol/L) 79.4 
(75.5, 83.5) 
67.7 
(64.7, 70.9) 
129.9 
(123.3, 136.9) 
138.0 
(131.2, 145.2) 
 
105.1 
(101.2, 109.1) 
68.7 
(66.1, 71.3) 
69.4 
(66.9, 72.0) 
81.5 
(78.2, 85.0) 
 
66.9 
(64.5, 69.5) 
 ADMA (µmol/L) 0.546 
(0.534, 0.558) 
0.532 
(0.521, 0.543) 
0.585 
(0.571, 0.598) 
0.559 
(0.546, 0.572) 
 
0.587 
(0.578, 0.597) 
0.572 
(0.563, 0.581) 
0.529 
(0.520, 0.538) 
0.563 
(0.553, 0.574) 
 
0.552 
(0.543, 0.561) 
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 SDMA (µmol/L) 0.555 
(0.539, 0.572) 
0.560 
(0.545, 0.575) 
0.636 
(0.617, 0.656) 
0.575 
(0.558, 0.592) 
 
0.713 
(0.697, 0.729) 
0.608 
(0.595, 0.622) 
0.592 
(0.579, 0.605) 
0.569 
(0.556, 0.583) 
 
0.599 
(0.586, 0.613) 
 hArg (µmol/L) 1.69 
(1.61, 1.78) 
1.60 
(1.52, 1.67) 
2.06 
(1.95, 2.17) 
1.84 
(1.75, 1.94) 
 
2.17 
(2.09, 2.25) 
2.50 
(2.40, 2.59) 
2.29 
(2.20, 2.38) 
2.27 
(2.17, 2.36) 
 
1.97 
(1.89, 2.04) 
 MMA (µmol/L) 0.191 
(0.181, 0.202) 
0.149 
(0.142, 0.157) 
0.158 
(0.149, 0.168) 
0.189 
(0.179, 0.200) 
 
0.200 
(0.192, 0.209) 
0.229 
(0.219, 0.238) 
0.193 
(0.185, 0.201) 
0.185 
(0.177, 0.194) 
 
0.176 
(0.169, 0.184) 
1MDCS, The Malmö Diet and Cancer Study; NSHDS, The Northern Sweden Health and Disease Study Cohort; ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; HUNT, The Nord-
Trøndelag Health Study; SMHS, The Shanghai Men’s Health Study; SWHS, The Shanghai Women’s Health Study; SCHS, The Singapore Chinese Health Study; SCS, The Shanghai Cohort Study; MCCS, The 
Melbourne Collaborative Cohort Study. 
2AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; BVS, B-Vitamin Score; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; 
FVS, Fat-soluble Vitamin Score; TOC, -tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine/tryptophan ratio; Kyn, kynurenine; MMA, 
methylmalonic acid; PA, 4-pyridoxic acid; PAr, PLP/(PL+PA); PL, pyridoxal; PLP, pyridoxal 5'-phosphate; QA, quinolinic acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; 
tMet, total methionine; Trp, tryptophan; TVS, Total Vitamin Score; Vit A, all-trans retinol; Vit D, 25-OH vitamin D2 + season adjusted 25-OH vitamin D3; XA, xanthurenic acid. 
3General linear models, adjusted for age, sex, smoking (former vs. never, current vs. never).  
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SUPPLEMENTAL TABLE 7 
Prevalence of vitamin deficiency by region1,2 
    
 Deficient, % of population 
 Total US, all US, no MV3 use US, MV3 use Nordic Asia Australia 
B2 3.3 1.4 1.8 0.8 4.2 6.3 0.3 
PLP 16.1 9.4 12.7 3.3 20.7 23.5 15.0 
Folate 1.9 0.5 0.6 0.4 6.0 1.5 3.7 
B12 0.8 0.8 0.9 0.7 0.6 0.8 1.1 
Vit A 0.2 0.2 0.2 0.1 0.0 0.3 0.0 
Vit D 9.1 7.3 9.5 3.3 4.8 14.7 4.5 
TOC 0.3 0.1 0.2 0.0 0.1 0.5 0.3 
1TOC, -tocopherol; B2, riboflavin; B12, vitamin B12; PLP, Pyridoxal 5'-
phosphate, Vit A, all-trans retinol; Vit D, season adjusted 25-OH vitamin D3+25-OH 
vitamin D2. 
2Cutoff concentrations for deficiency: TOC, 12 µmol/L; B2, 5 nmol/L; B12, 150 
pM; folate, 5 nmol/L; PLP, 20 nmol/L; vitamin A, 0.7 µmol/L; 25-OH vitamin D, 30 
nmol/L. 
3MV, Multivitamin supplement. 
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SUPPLEMENTAL TABLE 8 
Between-batch CV of the measured biomarkers in the quality control plasma1 
Vitamins 
 
CV (%)  
 
B2 7.1  
 
PLP 5.2  
 
PL 12.3  
 
PA 8.6  
 
Folate 9.5  
 
B12 6.8  
 
Vit A 6.6  
 25-OH Vit D2 n.a.2  
 
25-OH Vit D3 7.4  
 
TOC 6.2  
 
TOC 8.0  
One-carbon metabolites  
 
 
 
Met 2.0  
 
MetSO 28.7  
 
tHcy 3.4  
 
Cysta 3.8  
 
tCys 2.9  
 
Serine 2.5  
 
Glycine 2.5  
 
Choline 9.0  
 
Betaine 4.3  
 
DMG 8.3  
Tryptophan + metabolites  
 
 
 
Trp 2.9  
 
Kyn 2.5  
 
KA 5.5  
 
AA 14.1  
 
HK 8.1  
 
XA 14.6  
 
HAA 5.8  
 
QA 5.4  
Other  
  
 
 CRP 7.8  
 
Creat 3.9  
 
Cotinine 5.7  
 
Arginine 4.3  
 
ADMA 10.5  
 
SDMA 10.6  
 
hArg 10.2  
 
MMA 3.3  
 
1AA, anthranilic acid; ADMA, asymmetric dimethylarginine; -tocopherol, TOC; B2, riboflavin; B12, vitamin B12; CRP, C-reactive protein; 
Cysta, cystathionine; DMG, dimethylglycine; TOC, -tocopherol; HAA, 3-hydroxyanthranilic acid; hArg, homoarginine; HK, 3-hydroxykynurenine; 
KA, kynurenic acid; Kyn, kynurenine; MMA, methylmalonic acid; PA, 4-pyridoxic acid; PL, pyridoxal; PLP, pyridoxal 5'-phosphate; QA, quinolinic 
acid; SDMA, symmetric dimethylarginine, tCys, total cysteine; tHcy, total homocysteine; tMet, total methionine; Trp, tryptophan; Vit A, all-trans 
retinol; XA, xanthurenic acid. 
2In the QC plasma, 25-OH Vitamin D2 was below the LOD of the assay. 
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Supplemental Figure 1. Flow chart of participants  
5364 Participants 
5314 Participants included in analyses 
50 Participants excluded due to 
missing biomarker data 
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Supplemental Figure 2. Geometric means of the three vitamin scores. Black, US; green, Nordic; blue, Asia; red, Australia. Error 
bars indicate 95% CI. The B-Vitamin Score (BVS) was obtained from riboflavin, PLP, folate and vitamin B12, the Fat-soluble 
Vitamin Score (FVS) from vitamin A, total 25-
vitamins, as described in the text. Geometric means (95% CI) by region were estimated using mixed models adjusted for age, 
gender and smoking (former vs. never, current vs. never) with cohort as random effect. Geometric means (95% CI) by cohort were 
estimated by using generalized linear models adjusted for age, gender and smoking (former vs. never, current vs. never). MV, 
Multivitamin supplement. 
Cohort abbreviations: ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CLUE, The Campaign Against 
Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American Cancer 
Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health Professionals Follow-up Study; HUNT, The Nord-Trøndelag 
Health Study; MCCS, The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer Study; MEC, The 
Multiethnic Cohort; NHS, The Nurses’ Health Study; NSHDS, The Northern Sweden Health and Disease Study Cohort; 
NYUWHS, The New York University Women’s Health Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal 
and Ovarian  Cancer Screening Trial; SCCS, The Southern Community Cohort Study; SCHS, The Singapore Chinese Health 
Study; SCS, The Shanghai Cohort Study; SMHS, The Shanghai Men’s Health Study; SWHS, The Shanghai Women’s Health 
Study; WHI, The Women’s Health Initiative; WHS, Women’s Health Study. 
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Supplemental Figure 3. Distribution of vitamins and vitamin markers in USA by multivitamin supplement use from quantile 
regression (adjusted for age (years) at blood sampling, sex, smoking (former vs. never, current vs. never) and cohort) shown by 
(5,10,15,20,25,30,35, 40,45,50,55,60,65,70,75,80,85,90,95) percentiles. The y-axis in each panel is scaled to show three standard 
deviations of the distributions for the biomarker in that panel. The vertical line in each panel indicates the 50th quantile for each 
group. TOC, -tocopherol; TOC, -tocopherol HK, 3-hydroxykynurenine; HK/XA, HK/xanthurenic acid; MMA, 
methylmalonic acid; PLP, pyridoxal 5’-phosphate;  tHcy, total homocysteine; Total 25-OH vitamin D, 25-OH vitamin D2 + 
season-adjusted 25-OH vitamin D3. 
 
